

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Protocol for a prospective, international cohort study on the Management and Outcomes of Perioperative Care among European Diabetic Patients (MOPED)

|                               |   |
|-------------------------------|---|
| Journal:                      | <i>BMJ Open</i>   |
| Manuscript ID                 | bmjopen-2020-044394   |
| Article Type:                 | Protocol  |
| Date Submitted by the Author: | 08-Sep-2020   |
| Complete List of Authors:     | buggy , Donal; University College Dublin, ; Nolan, Rachel; Mater Misericordiae University Hospital, Anaesthesia Coburn, Mark; Medical Faculty, RWTH Aachen, Anesthesiology Columb, Malachy; Manchester University NHS Foundation Trust, Wythenshawe Hospital Acute Intensive Care Unit Hermanides, Jeroen; Amsterdam University Medical Centres, Department of Anesthesiology Hollman, M; AMC, Zarbock, Alexander; Universität Münster, |
| Keywords:                     | Adult anaesthesia < ANAESTHETICS, DIABETES & ENDOCRINOLOGY, SURGERY   |
|                               |   |

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Title:

**Protocol for a prospective, international cohort study on the Management and Outcomes of Perioperative Care among European Diabetic Patients (MOPED)**

Donal J. Buggy,<sup>1</sup> Rachel Nolan<sup>1</sup>, Marc Coburn,<sup>2</sup> Malachy Columb,<sup>3</sup> Jeroen Hermanides,<sup>4</sup> Markus W. Hollmann,<sup>4</sup> Alex Zarbock.<sup>5</sup>

<sup>1,6</sup> Department of Anaesthesiology and Perioperative Medicine, Mater University Hospital, School of Medicine, University College Dublin, Ireland;

<sup>2</sup> Department of Anaesthesiology and Perioperative Medicine, University of Bonn, Germany;

<sup>3</sup> Department of Anaesthesiology and Intensive Medicine, Manchester University Hospitals Foundation NHS Trust, Wythenshawe, United Kingdom;

<sup>4</sup> Department of Anesthesiology, Amsterdam University Medical Centers, location AMC, Amsterdam, Netherlands;

<sup>5</sup> Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, Germany.

<sup>6</sup> Collaborator, Outcomes Research Consortium, Cleveland Clinic, OH, USA.

Corresponding author:

Donal J Buggy donal.buggy@ucd.ie

Funding:

MOPED is sponsored by a grant from the European Society of Anaesthesiology Clinical Trial Network (ESA CTN).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 Author Contributions:  
4

5  
6 DJB: Concept instigation, ESA funding applicant, study design, manuscript draft;  
7

8 Malachy Colomb: : Study design, analysis plan draft;  
9

10 Marc Coburn: Study design, manuscript draft;  
11

12  
13 JH: Study design, manuscript draft;  
14

15 MWH: Study design, manuscript draft;  
16

17  
18 RN: Study design, manuscript draft;  
19

20 AZ: Study design, manuscript draft;  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract:**

**Introduction** - Diabetes is common (about 20m patients in Europe), and diabetic patients have more surgical interventions than the general population. There are plausible pathophysiology and clinical mechanisms that diabetic patients are at increased risk of postoperative complications. When postoperative complications occur in the general population, they increase major adverse events and subsequently increase one-year mortality. This is likely to be worse in diabetic patients. There is variation in practice guidelines in different countries in the perioperative management of diabetic patients undergoing major surgery, and whether this may affect postoperative outcome has not been investigated on a large scale. Neither is it known whether different strata of preoperative glycaemic control affects outcome.

**Methods and analysis** - A prospective, observational, international, multicentre cohort study, recruiting 5,000 patients in at least n=50 centres with diabetes undergoing elective or emergency surgery (NCT04511312). Inclusion criteria are any diabetic patient undergoing surgery under any substantive anaesthetic technique. Exclusion criteria are not confirmed diabetic patients, and diabetic patients undergoing procedures under monitored sedation or local anaesthetic infiltration only. Follow up duration to 30 days after surgery. Primary outcome is Days At Home at 30 days (DAH-30). Secondary outcomes are Comprehensive Complications Index (CCI), Quality of Recovery (QoR-15) Day 1, 30 -day mortality, length of hospital stay and incidence of specific major adverse events (MI, MINS, AKI, PPC, CVA, PE, DVT, Surgical Site Infection (SSI), Postoperative pulmonary infection (PPI)). Tertiary outcomes include time to resumption of normal diabetes therapy (insulin or oral

1  
2  
3 hypoglycaemics and diet), incidence of diabetic ketoacidosis or hypoglycaemia, incidence  
4  
5 and duration of use of IV insulin infusion therapy, and change in diabetic management at 30  
6  
7  
8 days.  
9

10  
11  
12  
13 **Ethics and dissemination** – This study will adhere to the principles of the Declaration of  
14  
15 Helsinki (amendment 2013) by the World Medical Association and the ICH-GCP Guidelines  
16  
17 E6(R2). Specific national and local regulatory authority requirements will be followed as  
18  
19 applicable. The main results of MOPED and its sub-studies will be published in peer-  
20  
21 reviewed international medical journals and presented at Euroanaesthesia congress and  
22  
23 other international and national meetings.  
24  
25  
26

27 ClinicalTrials.gov Identifier: NCT04511312  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## ARTICLE SUMMARY

### Strengths and limitations of this study:

1. There is wide variation in the perioperative anaesthetic management of diabetic patients, internationally and between centres. This will be the largest prospective, observational study documenting the influence of perioperative management on 30-day outcomes.
2. The primary endpoint is Days at Home at 30 days (DAH-30). This recently validated standardised end-point for perioperative trials (range 0-30 days, higher number indicating better outcome) gives a patient-centred outcome reflecting mortality, postoperative complications and return to independent living.
3. Secondary outcomes include Comprehensive Complications Index (CCI), a scale 0-100, higher number indicating worse outcome), based on the Clavien-Dindo scale of postoperative complications.
4. Broad inclusion criteria includes confirmed diabetic patients undergoing any surgery under any substantive anaesthetic technique. Excluded are procedures where local anaesthetic infiltration alone with or without monitored sedation. A maximum of 25% of cases evaluated will be ambulatory. This will enhance the external validity of the trial results and render it generalisable on a global scale.
5. The power of this study is driven by the target number 5,000 patients, which will enable more than 60 variables to be evaluated and up to ten a priori hypotheses to be tested.

1  
2  
3 **Keywords:** Diabetes, perioperative, complications, glycaemic control  
4  
5

6 **Word Count:** 3,146  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Introduction:

The incidence of diabetes is increasing globally, with an estimated 20 million diabetic patients in Europe, which is likely to increase, thereby adding to societal demands on European health services.[1] Diabetic patients are more likely to have surgical interventions than the general population.[2] There are plausible pathophysiology and clinical mechanisms that diabetics are at increased risk of postoperative complications.[3,4] When postoperative complications occur in the general population, they increase mortality or increase risk of major adverse cardiovascular events (Myocardial Infarction, Cerebrovascular Accident, Pulmonary embolism) at 30-days and up to one year later.[5-7] In addition, diabetes is an independent risk factor for surgical site infections [6].

National bodies in Europe and elsewhere differ in their guidelines on management of diabetic patients undergoing surgery and small observational studies confirm wide variability in practice and perioperative management between centres.[3,8] Given the multiplicity of guidelines and differing recommendations, it is unsurprising that variability of 'real-world' clinical practice with regard to perioperative management of oral antihyperglycemic medications and insulin therapy has been noted in audits such as the National Confidential Enquiry into Patient Outcome and Death (NCEPOD).[9] Whether this variability in practice affects postoperative outcome among diabetic patients in countries across Europe has not been investigated.

Further, although it is assumed that diabetic patients are at increased risk of postoperative complications[5-8], this has not been recently evaluated, especially in light of ongoing developments in perioperative care, such as Enhanced Recovery Programmes.[7] While a

1  
2  
3 quality improvement intervention study has shown that maintaining tight preoperative  
4 glycaemic control improves postoperative glycaemic control[10], it is not known if this  
5  
6 reduces postoperative morbidity overall. Moreover, whether certain anaesthetic techniques  
7  
8 may be associated with better or worse outcomes after major non-cardiac surgery is  
9  
10  
11  
12  
13 unknown.

14  
15  
16  
17  
18 Sub-group analysis will provide novel data on how patients with different strata (levels) of  
19  
20 preoperative glycaemic control progress in the postoperative period. Poor pre-operative  
21  
22 glycaemic control is associated with postoperative complications in retrospective  
23  
24 studies[10,11]. If this study confirms an association between the level of preoperative  
25  
26 glycaemic control and postoperative outcome, then the beginning of personalised  
27  
28 perioperative medicine for diabetic patients will be enabled. For example, it is known from  
29  
30 intensive care medicine that patients with better pre-admission glycaemic control (HbA1c <  
31  
32 53 mmol.mol) have worse outcomes if they develop hyperglycaemia, compared with patients  
33  
34 whose pre-existing glycaemic control was already poor (HbA1c > 69 mmol.mol) [4,11]. If this  
35  
36 pattern was reflected in the perioperative management of diabetic patients, it would enable a  
37  
38 more personalized approach in the perioperative period.  
39  
40  
41  
42  
43  
44  
45

46 This large, multicentre, international prospective observational study will address these  
47  
48 urgent research questions and will inform better management and outcomes for patients  
49  
50 undergoing surgery with this high risk, highly prevalent condition, which is increasing in  
51  
52 incidence in the European population.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Objectives –  
4

5  
6 To address the following research questions:  
7

- 8  
9  
10 1. What is the epidemiology of diabetic patients undergoing surgery across Europe: Are  
11  
12 there major variations in perioperative glycaemic control? Does management practice vary  
13  
14 between centres and between nations?  
15  
16  
17 2. What is the extent and patient-centred impact of postoperative complications among  
18  
19 diabetic patients up to 30 days after surgery in Europe?  
20  
21  
22 3. To undertake sub-group analysis comparing these outcomes among  
23  
24 a. Type 1, Type 2, and other diabetic patients;  
25  
26 b. Patients with different strata (levels) of glycaemic control, i.e. HbA1c <53, HbA1c  
27  
28 53-69 and HbA1c >69 mmol.mol;  
29  
30  
31 c. Patients who received different anaesthetic techniques: -Volatile versus total  
32  
33 intravenous anaesthesia; regional versus general anaesthesia (GA);  
34  
35  
36 d. Diabetics of longer duration have higher risk of intraoperative hypotension due to  
37  
38 autonomic neuropathy.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

#### Methods and Analysis:

Overall study design - MOPED is a prospective, observational, international, multicentre cohort study, supported by the European Society of Anaesthesiology (ESA). It has been registered on [clinicaltrials.gov](https://clinicaltrials.gov), NCT04511312.

Setting - Any hospital in Europe (as defined by the World Health Organisation) is welcome to participate as a study centre. Non-European centres may be accepted upon request to the Steering Committee. Centres will be asked to enroll a minimum of 45 patients to nominate one named co-investigator over a recruitment period of up to 18 months from the date of the centre's registration with ESA. No more than one quarter (25%) of a centre's patients can be day cases (ambulatory anaesthesia). Study centre registration will occur online via the dedicated "Call for Centres form" on the ESA website. Within the overall Europe-wide period of recruitment planned for MOPED (at least 18 months), the start of recruitment for individual centres is soon as possible after centre registration with ESA, provided that there is prior Institutional Review Board (IRB) approval. It is envisaged that at least n=50 centres will be actively enrolling patients. It is hoped that patients from at least ten nations will be enrolled. Enrollment will continue until the planned sample size (n=5,000) has been reached.

National coordinating investigators are anaesthesiologists appointed by ESA and the Steering Committee to lead the project within individual countries and their responsibility includes:

Identifying participating centres in their country and recruiting local co-ordinators in participating hospitals; Ensuring all necessary national or regional regulatory approvals are in place prior to start of patient inclusion; and facilitating good communication with ESA

1  
2  
3 headquarters and the participating sites in his/her countries during all study steps including  
4  
5 data cleaning. Local centre co-ordinators may be anesthesiologists, surgeons or diabetes  
6  
7 physicians working in perioperative medicine who will ensure all relevant regulatory/ethical  
8  
9 approvals are in place for their institution,  
10  
11  
12 supervise enrollment, daily data collection, and adjudicate morbidity events.  
13  
14  
15  
16  
17

#### 18 Participants:

19  
20 Inclusion criteria - Diabetic patients (all classes except gestational diabetes) undergoing  
21  
22 surgery with a substantive anaesthetic technique. This defined as requiring any general  
23  
24 anaesthesia technique or any specific regional anaesthetic technique or a combination.  
25  
26

27 Ambulatory, elective or emergency surgery and patients who receive postoperative care in  
28  
29 intensive care or high dependency units will be included. Pre-defined subgroups of diabetic  
30  
31 patients will be highlighted for later analysis.  
32  
33

34 Exclusion criteria - Patients who are not diabetic; Patients with gestational diabetes; Patients  
35  
36 undergoing surgery without a substantive anaesthetic technique, i.e. surgery under local  
37  
38 anaesthetic infiltration or topical anaesthesia alone with or without monitored sedation .  
39  
40  
41  
42  
43

44 Criteria for withdrawal or discontinuation of participants - Due to the observational nature of  
45  
46 the study, the protocol does not define any withdrawal/discontinuation criteria. Patients  
47  
48 electing to withdraw from the study may do so at any point. In this case, no further data will  
49  
50 be collected, while already collected, encoded data will be anonymised and analysis may be  
51  
52 performed up to the point of data collection. Withdrawing participants will not be replaced,  
53  
54 provided that their number does not exceed 5% of the projected sample size at the end of  
55  
56 the planned recruitment period.  
57  
58  
59  
60

1  
2  
3  
4  
5  
6 Participant information and informed consent - Written, informed consent, using the  
7  
8 approved Informed Consent Form (ICF), will be sought from each patient prior to inclusion  
9  
10 unless an explicit, written exemption by the responsible IRB is provided. Patient Information  
11  
12 Leaflet (PIL) and any other written information to be provided to the patients, as well as  
13  
14 advertisement for subject recruitment (if used) must be subject to the local IRB review and  
15  
16 given approval.  
17  
18  
19  
20  
21

#### 22 Variables:

23  
24  
25 Primary end point - Days at Home at 30 days (DAH-30) [12,13]. DAH-30 has been validated  
26  
27 as an outcome metric by numerous large scale cohort studies [13] as an end-point which  
28  
29 is pragmatic and easily obtained. It is affected by both patient factors (poor function, co-  
30  
31 morbidities) and surgical technique. DAH-30 is sensitive to surgical risk and impact of  
32  
33 post-operative complications in that it accounts for both delayed discharge and re-  
34  
35 admission.  
36  
37  
38

39  
40 Secondary end points - Comprehensive Complications Index (CCI) score, based on Clavien-  
41  
42 Dindo scale;[14,15] Quality of Recovery scale (QoR-15), only taken from patients who are in  
43  
44 hospital the day after surgery, i.e. Day 1 postoperatively [16], 30-day mortality, Length of  
45  
46 Stay in Hospital, Length of Stay in ICU if applicable; Incidence of specific major adverse  
47  
48 events as listed in European Perioperative Clinical Outcomes Definitions manuscript[17].  
49  
50

51 These and other outcomes are shown in Table 1.  
52  
53  
54  
55

56 Data sources: The following data will be extracted from clinical charts: age, gender, weight,  
57  
58 height, variables for CCI, variables for SORT calculation (SORT score Appendix 3).  
59  
60



1  
2  
3  
4 ASA classification, relevant medical history, preoperative diabetes medication (substance  
5  
6 classes only), type of anaesthesia, date, type, and location of surgery, procedure duration,  
7  
8 type and date if ICU admission, date of discharge from ICU and from hospital. For details,  
9  
10 please see the CRF. Patients' consent will be requested to allow documentation of their  
11  
12 perioperative course and 30-day outcome as outlined in the outcome measures.  
13  
14  
15  
16  
17

18 Bias - In every centre, all diabetic patients undergoing surgery, (except where there is only  
19  
20 conscious sedation, with or without local anaesthetic infiltration or topical anaesthesia to the  
21  
22 eye) are eligible. Centres are invited to enrol their target number of patients (depending on  
23  
24 number of investigators in their team) from date of registration of their centre with ESA for up  
25  
26 to 12 months. No other exclusion criteria apply, even emergency surgery patients are  
27  
28 eligible. Therefore, we do not believe that significant risk of bias exists.  
29  
30  
31  
32  
33  
34

35 Study procedures:

36 Recruitment and screening -

37  
38  
39 At screening day ("day -90" to "day of surgery", i.e. within 3 months of planned day of  
40  
41 surgery), patients will be screened and be asked for consent. Diabetic patients listed for both  
42  
43 elective and emergency surgery will be approached by a member of the research team and  
44  
45 invited to participate. They will be offered a Patient Information Leaflet and the investigator  
46  
47 will withdraw to allow the patient to consider it by themselves. The team member will then  
48  
49 obtain signed written consent if the patient agrees to proceed. While for elective patients,  
50  
51 consent may be obtained in a preoperative clinic up to 90 days prior, for emergency surgery  
52  
53 diabetic patients' consent may be requested on the ward, immediately prior to coming to  
54  
55 theatre on the day of surgery. This is justified because there is even less knowledge  
56  
57  
58  
59  
60

1  
2  
3 currently about the management and outcomes of diabetic patients undergoing *emergency*  
4 surgery, who are acknowledged to be a particularly high-risk group, compared to diabetic  
5 patients undergoing elective surgery. Therefore, including a cohort of these patients is  
6 particularly important to evaluate risk factors for adverse outcomes which may be mitigated.  
7  
8 There is also anecdotal evidence that practice of managing these patients varies widely  
9 between nations and individual centres.

10  
11  
12  
13 The Surgical Outcome Risk Tool (SORT) will be used to indicate surgical risk [17]

14  
15  
16  
17  
18  
19  
20  
21  
22 If patients remain in hospital on the day after surgery, some data will be documented  
23 including QoR-15 quality of recovery score, taking 3-5 minutes. Some patient data will also  
24 be recorded on Day of Discharge, provided patient is discharged within 30 days of their  
25 surgery. At Day 30 after surgery, data will be collected by telephone if the patient has been  
26 discharged. If still in hospital, patient data will be collected on the ward on Day 30. See  
27  
28  
29  
30  
31  
32  
33  
34

35 Figure 1: Study Flow Table

36  
37  
38  
39 Data collection:

40  
41  
42 At the end of the study period each center will provide an “end of study reporting form” (see  
43 Appendix 8) to report the number of patients meeting the inclusion criteria during the study  
44 period and the total number of screening failure patients. Furthermore, each center will provide  
45 a Screening Failure Tracking Form (Appendix 9) giving the reasons for screening failures at  
46 the end of the study period. Using this form, it will be possible to analyse what are the reasons  
47 for exclusion from study (e.g. subject refused to sign informed consent, subject is already  
48 participating in other clinical trial, subject language, cognitive difficulties, etc). Data will be  
49 collected at each centre, anonymised, and entered into a bespoke electronic case-report form  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (eCRF). Completed forms will be submitted to the sponsor at the ESA Clinical Trials Network  
4  
5  
6 (ESA CTN) in Brussels, Belgium.  
7  
8  
9

10 Statistical methodology:

11  
12 Sample size estimation - Up to 5% of the population of Europe is thought to have diabetes.

13  
14 About 30 million surgeries are performed in Europe per annum, therefore perhaps 1.5 million  
15  
16 diabetics have surgery in Europe each year. It is proposed to evaluate a pragmatic sample  
17  
18 of 5,000 European diabetic patients across at least 50 centres in a minimum of 15 nations. It  
19  
20 is expected that this should be sufficient for the main epidemiological aspects of this study. It  
21  
22 is envisaged that this target number would be enrolled over a two-year period from initial roll-  
23  
24 out, with up to a further 12 months needed for final data acquisition, data cleaning and  
25  
26 analysis. A sample size of 5,000 should be sufficient to avoid over-fitting and variance  
27  
28 inflation for 50 to 70 factors and interactions based on the conventional square root or 100  
29  
30 values per variable respectively. In addition, a sample size of 5,000 will have at least 90%  
31  
32 power to find a small standardized difference of 0.15 as significant at  $P < 0.05$  (Bonferroni  
33  
34 corrected at  $P < 0.0007$ ) for up to 70 independent hypotheses and in comparing subsets of  
35  
36 interest.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 The aim of this research is to describe and quantify the epidemiology of the perioperative  
48  
49 management of diabetic patients in Europe. Descriptive statistics such as mean (SD),  
50  
51 median [interquartiles, range] and frequencies (%) will be presented as appropriate. The  
52  
53 precision of the estimates will be reported with 95% confidence intervals to show the  
54  
55 prevalence and incidence rates of diabetic phenotypes and major adverse events and  
56  
57 complications. A further publication of the Study analysis plan is in preparation.  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11 GDPR, Data and Quality Management:

12  
13 Quality control measures will be applied to each stage of data handling to ensure that all  
14 data are reliable and have been processed correctly, including written SOP (in English for all  
15 countries) for data collection and entry, automated consistency checks, and training of  
16 National Coordinating Investigator and local PI. It will be responsibility of the National  
17 Coordinating Investigator, with support by the study coordinating office, to train local PI.  
18  
19 Local centre coordinators will ensure that the data in the eCRF are carefully entered and  
20 verified regularly. It will be the responsibility of local coordinators to conduct periodic and  
21 random checks to ensure data quality in her/his centre. The ESA, as sponsor is responsible  
22 for securing agreement from all involved parties to ensure direct access to all trial related  
23 sites, source data/documents for the purpose of monitoring and auditing. No fee or financial  
24 compensation is given to any co-investigator or participating institution for patient  
25 recruitment.  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Data Handling - Data will be entered into a secure on-line database protected by  
45 personalised and confidential usernames and passwords and documenting the time and  
46 individual entering the data. The language of the online database, eCRF, and the relative  
47 SOPs is English and will not be translated in the national languages. Data will be collected  
48 directly from source documents into the encoded paper CRF and secondarily entered into  
49 the eCRF. A copy of the original source documents will be stored within a locked  
50 cabinet/office accessible to authorised personnel only in accordance with local and national  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 regulations. All study documents will be archived as required by local legislation. Sponsor  
4  
5 and centres will maintain and update their trial master files according to the recommendation  
6  
7 of the ICH-GCP Guidelines E6(R2).  
8  
9

10  
11  
12  
13 Confidentiality and Data protection - To safeguard patients' confidentiality, a patient  
14  
15 identification code will be assigned to encode data. The confidential log linking patient  
16  
17 identification code and identifiable patient data will be stored separately in a locked cabinet  
18  
19 accessible to authorised personnel only and corresponding electronic files will be protected  
20  
21 by personalised and confidential usernames and passwords. eCRF are identified through  
22  
23 the patient identification code and will not include any names, initials, date of birth or local  
24  
25 hospital patient numbers; therefore, no patient identifiable data will be directly accessible  
26  
27 from the eCRF. Open direct access to all relevant trial information as well as source  
28  
29 data/documents will be permitted for purposes of monitoring, audits or inspections to the  
30  
31 sponsor, national coordinators, IRB, or regulatory authorities. All handling of personal data  
32  
33 will comply with the GCP Guidelines and follow strictly the legal and national requirements  
34  
35 for data protection.  
36  
37  
38  
39

40  
41 Patient and Public Involvement – To maximise the benefit of this study to patients we  
42  
43 prioritised using a patient-centric, holistic primary outcome; Days at Home at 30 days.  
44  
45 Previous delphi process driven studies have shown this to be a sensitive index of  
46  
47 postoperative complications and their impact on patients' lives. Ireland's diabetes patient  
48  
49 advocacy association, Diabetes Ireland, kindly reviewed the draft protocol and offered  
50  
51 comment and suggestion which influenced the final draft.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Publication and dissemination of results:

5  
6 The main results of MOPED and its sub-studies will be published in peer-reviewed  
7  
8 international medical journals and presented at Euroanaesthesia and at international and  
9  
10 national meetings. As recommended by the International Committee of Medical Journal  
11  
12 Editors ([http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-](http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html)  
13  
14 *the-role-of-authors-and-contributors.html*; accessed August 30th 2016), authorship will be  
15  
16 considered based on contributions to recruitment of patients, data acquisition and cleaning,  
17  
18 analysis and interpretation of the data, manuscript writing, and submission of national/local  
19  
20 grants AND final approval of the version to be published AND agreement to be accountable  
21  
22 for all aspects of the work in ensuring that questions related to the accuracy or integrity of  
23  
24 any part of the work are appropriately investigated and resolved. The Steering Committee  
25  
26 (SC) will also be the Writing Committee (WC).  
27  
28  
29  
30  
31  
32  
33

34 All papers derived from the MOPED database will be published under the acronym "The  
35  
36 MOPED Investigators". All authors will be specifically named, in order to give every  
37  
38 investigator the same credit and the same responsibilities for successfully performing this  
39  
40 study. All authors will be mentioned with their name and affiliation in the collaborators list  
41  
42 which will be published in an appendix to the manuscript. The members of the Steering-  
43  
44 Writing committee will be specifically identified as required by most journals. Collaborators  
45  
46 names will be listed in PubMed.  
47  
48  
49  
50  
51  
52

53 It is the responsibility of the local coordinators to determine who is to be considered as  
54  
55 investigator. The local PI will be asked to submit names of staff actively involved from their  
56  
57 institution in the End of Study Reporting Form. If the number of recruited patients from a  
58  
59  
60

1  
2  
3 centre is too low to justify sufficient active involvement, the SC may decide on the legitimacy  
4 of collaboratorship based on other contributions. The final decision will be left to the SC in  
5  
6 consultation with the ESA. The number of investigators allowed from each centre will be  
7  
8 determined by the number of patients enrolled by that centre. TNo more than 25% of a  
9  
10  
11  
12  
13 centre's enrolled patients should be day cases (ambulatory anaesthesia).  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 Presentation at international meetings will be restricted to the members of the SC or their  
29  
30 delegates. National Coordinators will qualify for presentation at national meetings after  
31  
32 approval by the SC and the sponsor. ESA Clinical Trial Network will be acknowledged in all  
33  
34 publications and presentations.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 After publication of the pooled results, centres will be allowed to use their own anonymised  
50  
51 data for local presentation and publication. Duplicate data publication is not permitted.  
52  
53  
54  
55  
56  
57  
58  
59  
60

The Sponsor and the SC have the right to veto the nesting of a study into MOPED. The  
publication of any study nested within MOPED will occur after publication of the main results  
of MOPED (main objectives 1 and 2). For transparency, the original paper should be  
referenced to in all articles of nested analyses. Authorship rules for potential publications

1  
2  
3 derived from such nested cohort studies are to be submitted to the Sponsor and SC together  
4  
5  
6 with the study proposal.  
7

8 Requests for data sharing for individual-level meta-analyses are to be addressed to the  
9  
10 Sponsor and SC.  
11

12  
13 The sponsor of the study (ESA CTN) can use anonymised pooled data for internal analyses  
14  
15 and educational purposes.  
16

17  
18  
19  
20 Figure Legend:

21  
22 Table 1: Study end-points

23  
24  
25 Figure 1: Study work flow  
26  
27  
28  
29

30 References:

- 31  
32 1. International diabetes federation, Cho NH, Kirigia J, Claude J et al. IDF diabetes atlas 8<sup>th</sup>  
33 ed. 2019: Visit: <http://www.diabetesatlas.org/resources/2017-atlas.html>. [accessed 22 Jan  
34  
35 2020]  
36  
37  
38  
39 2. Frisch A, Chandra P, Smiley D, et al. Prevalence and clinical outcome of hyperglycaemia  
40 in the perioperative period in non-cardiac surgery. *Diabetes Care* 2010;33:1783-88.  
41  
42  
43  
44 3. Hulst A, Hermanides J, Hollmann MW, DeVries JH, Preckel B. Lack of Consensus on  
45 Peri-Operative Management of Patients with Diabetes Mellitus. *Eur J Anaesthesiol* 2019  
46 Feb;36(2):168-169.  
47  
48  
49  
50 4. Plummer MP, Bellomo R, Cousins CE, et al. Dysglycaemia in the critically ill and the  
51 interaction of chronic and acute glycaemia with mortality. *Intensive Care Med.* 2014  
52 Jul;40(7):973-80. doi: 10.1007/s00134-014-3287-7. Epub 2014 Apr 24.  
53  
54  
55  
56  
57  
58  
59  
60




- 1  
2  
3  
4 5. Umpierrex G, Smiley D, Jacobs S et al. Randomised study of basal-bolus insulin therapy  
5  
6 in the management of patients with type 2 diabetes undergoing general surgery (RABBIT  
7  
8 2 surgery). *Diabetes Care* 2011;34:256-61.
- 9  
10 6. Emily T Martin 1, Keith S Kaye 2, Caitlin Knott. Diabetes and Risk of Surgical Site  
11  
12 Infection: A Systematic Review and Meta-analysis *Infect Control Hosp Epidemiol* 2016  
13  
14 Jan;37(1):88-99. doi: 10.1017/ice.2015.249. Epub 2015 Oct 27.
- 15  
16 7. Vascular events in non-cardiac surgery patients cohort evaluation (VISION  
17  
18 investigators). Association between complications and death within 30 days after  
19  
20 noncardiac surgery. *CMAJ* 2019;191:E830-37.
- 21  
22 8. Kuzulugil D, Papeix G, Luu J, Kerridge R. Recent advances in diabetes treatments and  
23  
24 their perioperative implications. *Current Opinion in Anaesthesiology* 2019;32:398-404.
- 25  
26 9. National Confidential Enquiry into Patient Outcome and Death. Highs and Lows, London,  
27  
28 2018. Visit:  
29  
30 [https://www.ncepod.org.uk/2018pd/Highs%and%20Lows\\_Summary%20Report.pdf](https://www.ncepod.org.uk/2018pd/Highs%and%20Lows_Summary%20Report.pdf).  
31  
32  
33  
34  
35  
36  
37 Accessed 22 January 2020
- 38  
39 10. Garg R, Schuman B, Bader A et al. Effect of preoperative diabetes management on  
40  
41 glycaemic control and clinical outcomes after elective surgery. *Ann Surg* 2018;267:858-  
42  
43 62.
- 44  
45 11. Giuseppe Gatti 1, Andrea Perrotti, Daniel Reichart. Glycated Hemoglobin and Risk of  
46  
47 Sternal Wound Infection After Isolated Coronary Surgery. *Circ J* 2016 Dec 22;81(1):36-  
48  
49 43. doi: 10.1253/circj.CJ-16-0778.
- 50  
51 12. Bell M, Erikson L, Svensson T et al. Days at home after surgery: an integrated and  
52  
53  
54  
55  
56 efficient outcome measure for clinical trials and quality assurance. *E-Clinical*  
57  
58  
59  
60 *Medicine* 2019;11:18-26.

- 1  
2  
3  
4 13. Myles PS, Shulman M, Heritier S et al. Validation of days at home as an outcome  
5  
6 measure after surgery: A prospective cohort study. *BMJ Open* 2017;7:E015828  
7  
8  
9 14. Slankamenac K, Nederlof N, Pessaux P, et al. The comprehensive complications index:  
10  
11 a novel and more sensitive endpoint for assessing outcome and reducing sample size in  
12  
13 randomized controlled trials. *Ann Surg* 2014; 260(5):757-62; discussion 762-3.  
14  
15 15. Clavien PA, Vetter D, Staiger RD, et al. The Comprehensive Complication Index  
16  
17 (CCI(R)): Added Value and Clinical Perspectives 3 Years "Down the Line". *Ann Surg*  
18  
19 2017; 265(6):1045-1050.  
20  
21  
22 16. Stark PA, Myles PS, Burke JA. Development and Psychometric Evaluation of a  
23  
24 Postoperative Quality of Recovery Score. The QoR-15. *Anesthesiology*  
25  
26 2013;118(6):1332-40.  
27  
28  
29 17. Protopappa KL, Simpson JC, Smith N, Moonesinghe R. Development and validation of  
30  
31 the surgical outcome risk tool (SORT). *Br J Surg* 2014;101:1774-83.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1: Study End-Points

| Primary                 | Secondary                                  | Tertiary   |
|-------------------------|--|--|
| Days at Home at 30 days | Comprehensive Complications Index          | Time to resumption of normal diabetes therapy                |
|                         | Quality of Recovery scale (QoR-15)         | Incidence of diabetic ketoacidosis or hypoglycaemia          |
|                         | 30-day mortality                           | incidence and duration of use of IV insulin infusion therapy |
|                         | Length of Stay in Hospital                 | Incidence of diabetic ketoacidosis or hypoglycaemia          |
|                         | Length of Stay in ICU (if applicable)      | Change in diabetic management at 30 days                     |
|                         | Incidence of specific major adverse events |  |

Figure 1: Study Work Flow



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

|                              | Item No | Recommendation  |
|------------------------------|---------|---|
| <b>Title and abstract</b>    | 1       | (a) Indicate the study's design with a commonly used term in the title or the abstract<br>(b) Provide in the abstract an informative and balanced summary of what was done and what was found   |
| <b>Introduction</b>          |         |   |
| Background/rationale         | 2       | Explain the scientific background and rationale for the investigation being reported  |
| Objectives                   | 3       | State specific objectives, including any prespecified hypotheses  |
| <b>Methods</b>               |         |   |
| Study design                 | 4       | Present key elements of study design early in the paper   |
| Setting                      | 5       | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection   |
| Participants                 | 6       | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br>(b) For matched studies, give matching criteria and number of exposed and unexposed   |
| Variables                    | 7       | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable  |
| Data sources/<br>measurement | 8*      | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group  |
| Bias                         | 9       | Describe any efforts to address potential sources of bias   |
| Study size                   | 10      | Explain how the study size was arrived at   |
| Quantitative variables       | 11      | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why  |
| Statistical methods          | 12      | (a) Describe all statistical methods, including those used to control for confounding<br>(b) Describe any methods used to examine subgroups and interactions<br>(c) Explain how missing data were addressed<br>(d) If applicable, explain how loss to follow-up was addressed<br>(e) Describe any sensitivity analyses  |
| <b>Results</b>               |         |   |
| Participants                 | 13*     | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed<br>(b) Give reasons for non-participation at each stage<br>(c) Consider use of a flow diagram   |
| Descriptive data             | 14*     | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders<br>(b) Indicate number of participants with missing data for each variable of interest<br>(c) Summarise follow-up time (eg, average and total amount)  |
| Outcome data                 | 15*     | Report numbers of outcome events or summary measures over time  |
| Main results                 | 16      | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included<br>(b) Report category boundaries when continuous variables were categorized<br>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |

|    |                          |    |  |
|----|--------------------------|----|--|
| 1  | Other analyses           | 17 | Report other analyses done—eg analyses of subgroups and interactions, and              |
| 2  |                          |    | sensitivity analyses   |
| 3  | <hr/>                    |    |  |
| 4  | <b>Discussion</b>        |    |  |
| 5  | Key results              | 18 | Summarise key results with reference to study objectives                               |
| 6  | Limitations              | 19 | Discuss limitations of the study, taking into account sources of potential bias or     |
| 7  |                          |    | imprecision. Discuss both direction and magnitude of any potential bias                |
| 8  | <hr/>                    |    |  |
| 9  | Interpretation           | 20 | Give a cautious overall interpretation of results considering objectives, limitations, |
| 10 |                          |    | multiplicity of analyses, results from similar studies, and other relevant evidence    |
| 11 | <hr/>                    |    |  |
| 12 | Generalisability         | 21 | Discuss the generalisability (external validity) of the study results                  |
| 13 | <hr/>                    |    |  |
| 13 | <b>Other information</b> |    |  |
| 14 | Funding                  | 22 | Give the source of funding and the role of the funders for the present study and, if   |
| 15 |                          |    | applicable, for the original study on which the present article is based               |
| 16 | <hr/>                    |    |  |

17  
18 \*Give information separately for exposed and unexposed groups.

19  
20  
21 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and  
22 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely  
23 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
24 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
25 available at <http://www.strobe-statement.org>.

# BMJ Open

## Protocol for a prospective, international cohort study on the Management and Outcomes of Perioperative Care among European Diabetic Patients (MOPED)

|                                 |   |
|---------------------------------|---|
| Journal:                        | <i>BMJ Open</i>   |
| Manuscript ID                   | bmjopen-2020-044394.R1  |
| Article Type:                   | Protocol  |
| Date Submitted by the Author:   | 16-Mar-2021   |
| Complete List of Authors:       | buggy , Donal; University College Dublin, ; Nolan, Rachel; Mater Misericordiae University Hospital, Anaesthesia Coburn, Mark; Medical Faculty, RWTH Aachen, Anesthesiology Columb, Malachy; Manchester University NHS Foundation Trust, Wythenshawe Hospital Acute Intensive Care Unit Hermanides, Jeroen; Amsterdam University Medical Centres, Department of Anesthesiology Hollman, M; AMC, Zarbock, Alexander; Universität Münster, |
| <b>Primary Subject Heading</b>: | Anaesthesia   |
| Secondary Subject Heading:      | Diabetes and endocrinology, Surgery   |
| Keywords:                       | Adult anaesthesia < ANAESTHETICS, DIABETES & ENDOCRINOLOGY, SURGERY   |
|                                 |   |

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Title:

**Protocol for a prospective, international cohort study on the Management and Outcomes of Perioperative Care among European Diabetic Patients (MOPED)**

Donal J. Buggy,<sup>1,6</sup> Rachel Nolan<sup>1</sup>, Mark Coburn,<sup>2</sup> Malachy Columb,<sup>3</sup> Jeroen Hermanides,<sup>4</sup> Markus W. Hollmann,<sup>4</sup> Alex Zarbock.<sup>5</sup>

<sup>1</sup>Department of Anaesthesiology and Perioperative Medicine, Mater University Hospital, School of Medicine, University College Dublin, Ireland;

<sup>2</sup>Department of Anaesthesiology and Perioperative Medicine, University of Bonn, Germany;

<sup>3</sup>Department of Anaesthesiology and Intensive Medicine, Manchester University Hospitals Foundation NHS Trust, Wythenshawe, United Kingdom;

<sup>4</sup>Department of Anesthesiology , Amsterdam University Medical Centers, location AMC, Amsterdam, Netherlands;

<sup>5</sup>Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, Germany.

<sup>6</sup>Collaborator, Outcomes Research Consortium, Cleveland Clinic, OH, USA.

Corresponding author:

Donal J Buggy donal.buggy@ucd.ie

Author Contributions:

DJB: Concept instigation, ESA applicant, study design, manuscript draft;

Malachy Colomb: : Study design, analysis plan draft;

1  
2  
3 Marc Coburn: Study design, manuscript draft;  
4

5  
6 JH: Study design, manuscript draft;  
7

8 MWH: Study design, manuscript draft;  
9

10 RN: Study design, manuscript draft;  
11

12  
13 AZ: Study design, manuscript draft;  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Abstract:**

**Introduction:** Diabetes is common (about 20m patients in Europe), and diabetic patients have more surgical interventions than the general population. There are plausible pathophysiological and clinical mechanisms suggesting that diabetic patients are at increased risk of postoperative complications. When postoperative complications occur in the general population, they increase major adverse events and subsequently increase one-year mortality. This is likely to be worse in diabetic patients. There is variation in practice guidelines in different countries in the perioperative management of diabetic patients undergoing major surgery, and whether this may affect postoperative outcome has not been investigated on a large scale. Neither is it known whether different strata of preoperative glycaemic control affects outcome.

**Methods and analysis:** A prospective, observational, international, multicentre cohort study, recruiting 5,000 diabetic patients undergoing elective or emergency surgery in at least n=50 centres (NCT04511312). Inclusion criteria are any diabetic patient undergoing surgery under any substantive anaesthetic technique. Exclusion criteria are not being a confirmed diabetic patient and diabetic patients undergoing procedures under monitored sedation or local anaesthetic infiltration only. Follow up duration is 30 days after surgery. Primary outcome is Days At Home at 30 days (DAH-30). Secondary outcomes are Comprehensive Complications Index (CCI), Quality of Recovery (QoR-15) Day 1, 30 -day mortality, length of hospital stay and incidence of specific major adverse events (MI, MINS, AKI, PPC, CVA, PE, DVT, Surgical Site Infection (SSI), Postoperative pulmonary infection (PPI)). Tertiary outcomes include time to resumption of normal diabetes therapy, incidence of diabetic

1  
2  
3 ketoacidosis or hypoglycaemia, incidence and duration of use of IV insulin infusion therapy,  
4  
5  
6 and change in diabetic management at 30 days.  
7  
8  
9

10 **Ethics and dissemination:** This study will adhere to the principles of the Declaration of  
11  
12 Helsinki (amendment 2013) by the World Medical Association and the ICH-GCP Guidelines  
13  
14 E6(R2). Specific national and local regulatory authority requirements will be followed as  
15  
16 applicable. The main results of MOPED and its sub-studies will be published in peer-  
17  
18 reviewed international medical journals and presented at Euroanaesthesia congress and  
19  
20 other international and national meetings.  
21  
22  
23

24  
25 ClinicalTrials.gov Identifier: NCT04511312  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ARTICLE SUMMARY

### Strengths and limitations of this study:

1. There is wide variation in the perioperative anaesthetic management of diabetic patients, internationally and between centres. This will be the largest prospective, observational study documenting the influence of perioperative management on 30-day outcomes.
2. The primary endpoint is Days at Home at 30 days (DAH-30). This recently validated standardised end-point for perioperative trials (range 0-30 days, higher number indicating better outcome) gives a patient-centred outcome reflecting mortality, postoperative complications and return to independent living.
3. Secondary outcomes include Comprehensive Complications Index (CCI), a scale 0-100, higher number indicating worse outcome), based on the Clavien-Dindo scale of postoperative complications.
4. Broad inclusion criteria includes confirmed diabetic patients undergoing any surgery under any substantive anaesthetic technique. Excluded are procedures where local anaesthetic infiltration alone with or without monitored sedation. A maximum of 25% of cases evaluated will be ambulatory. This will enhance the external validity of the trial results and render it generalisable on a global scale.
5. The power of this study is driven by the target number 5,000 patients, which will enable more than 60 variables to be evaluated and up to eleven a priori hypotheses to be tested.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Keywords:** Diabetes, perioperative, complications, glycaemic control

**Word Count:** 3,146

For peer review only

## Introduction:

The incidence of diabetes is increasing globally, with an estimated 20 m diabetic patients in Europe. This is likely to increase, adding to societal demands on European health services.[1] Diabetic patients are more likely to have surgical interventions than the general population.[2] There are plausible pathophysiological and clinical mechanisms that diabetic patients are at increased risk of postoperative complications.[3,4] When postoperative complications occur in the general population, they increase mortality or risk of major adverse cardiovascular events (Myocardial Infarction, Cerebrovascular Accident, Pulmonary embolism) at 30-days and up to one year later.[5-7] In addition, diabetes is an independent risk factor for surgical site infections [6].

National bodies in Europe and elsewhere differ in their guidelines on management of diabetic patients undergoing surgery and small observational studies confirm wide variability in practice and perioperative management between centres.[3,8] Given the multiplicity of guidelines and differing recommendations, it is unsurprising that variability of 'real-world' clinical practice regarding perioperative management of oral antihyperglycemic medications and insulin therapy has been observed in audits such as the National Confidential Enquiry into Patient Outcome and Death (NCEPOD).[9] Whether this variability in practice affects postoperative outcome among diabetic patients in Europe or elsewhere has not been investigated.

Further, although it is assumed that diabetic patients are at increased risk of postoperative complications[5-8], this has not been evaluated recently, especially in light of ongoing developments in perioperative care, such as Enhanced Recovery Programmes.[7] While a

1  
2  
3 quality improvement intervention study has shown that maintaining tight preoperative  
4 glycaemic control improves postoperative glycaemic control[10], it is not known if this  
5  
6 reduces postoperative morbidity overall. Moreover, whether certain anaesthetic techniques  
7  
8 may be associated with better or worse outcomes after major non-cardiac surgery is  
9  
10  
11  
12  
13 unknown.

14  
15  
16  
17  
18 Sub-group analysis will provide novel data on how patients with different strata (levels) of  
19  
20 preoperative glycaemic control progress in the postoperative period. Poor pre-operative  
21  
22 glycaemic control is associated with postoperative complications in retrospective  
23  
24 studies[10,11]. If this prospective study confirms an association between the level of  
25  
26 preoperative glycaemic control and postoperative outcome, then the beginning of  
27  
28 personalised perioperative medicine for diabetic patients might be enabled. For example, it  
29  
30 is known from intensive care medicine that patients with better pre-admission glycaemic  
31  
32 control (HbA1c < 53 mmol.mol) have worse outcomes if they develop hyperglycaemia,  
33  
34 compared with patients whose pre-existing glycaemic control was already poor (HbA1c > 69  
35  
36 mmol.mol) [4,11].  
37  
38  
39  
40  
41  
42  
43

44 This large, multicentre, international, prospective observational study will address these  
45  
46 urgent research questions and will inform better management and outcomes for patients  
47  
48 undergoing surgery with this high risk, highly prevalent condition, which is increasing in  
49  
50 incidence in the European population.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Objectives –  
4

5  
6 To address the following research questions:  
7

8  
9  
10 1. What is the epidemiology of diabetic patients undergoing surgery across Europe: Are  
11  
12 there major variations in perioperative glycaemic control? Does management practice vary  
13  
14 between nations?  
15

16  
17 2. What is the extent and patient-centred impact of postoperative complications among  
18  
19 diabetic patients up to 30 days after surgery in Europe?  
20  
21

22 3. To undertake sub-group analysis comparing:  
23

24 a. Type 1, Type 2, and other diabetic patients;  
25

26 b. Patients with different strata (levels) of glycaemic control, i.e. HbA1c <53, HbA1c  
27  
28 53-69 and HbA1c >69 mmol.mol;  
29

30  
31 c. Patients who received different anaesthetic techniques: -Volatile versus total  
32  
33 intravenous anaesthesia; regional versus general anaesthesia (GA);  
34

35  
36 d. Whether diabetic patients of longer duration versus more recently diagnosed  
37  
38 diabetic patients have higher risk of intraoperative hypotension due to autonomic  
39  
40 neuropathy.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

#### Methods and Analysis:

Overall study design - MOPED is a prospective, observational, international, multicentre cohort study, supported by the European Society of Anaesthesiology (ESA). It has been registered on [clinicaltrials.gov](https://clinicaltrials.gov), NCT04511312.

Setting - Any hospital in Europe (as defined by the World Health Organisation) is welcome to participate as a study centre. Non-European centres may be accepted upon request to the Steering Committee. Centres will be asked to enroll a minimum of 45 patients, in order to nominate one named co-investigator. The recruitment period will be up to 18 months from the date of the centre's registration with ESA. No more than one quarter (25%) of a centre's patients can be day cases (ambulatory anaesthesia). Study centre registration will occur online via the dedicated "Call for Centres form" on the ESA website. The start of recruitment for individual centres should be soon as possible after centre registration with ESA, provided that there is prior Institutional Review Board (IRB) approval. It is envisaged that at least n=50 centres will actively enroll patients. It is hoped that patients from at least ten nations will be enrolled. Enrollment will continue until the planned sample size (n=5,000) has been reached.

National coordinating investigators are anaesthesiologists appointed by ESA and the Steering Committee to lead the project within individual countries. Their responsibility includes:

Identifying participating centres in their country and recruiting local co-ordinators in participating hospitals; Ensuring all necessary national or regional regulatory approvals are in place prior to start of patient inclusion; facilitating good communication between ESA headquarters and the participating sites in that nation. Local centre co-ordinators may be

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

anesthesiologists, surgeons or diabetes physician working in perioperative medicine who will ensure all relevant regulatory/ethical approvals are in place for their institution, and who will supervise enrollment, data collection and adjudicate morbidity events.

#### Participants:

Inclusion criteria - Diabetic patients (all classes except gestational diabetes) undergoing surgery with a substantive anaesthetic technique will be included. A substantive anaesthetic technique is defined as one requiring any general anaesthesia or any specific regional anaesthetic technique or a combination. Ambulatory, elective or emergency surgery and patients who receive postoperative care in intensive care or high dependency units will be included. Pre-defined subgroups of diabetic patients will be highlighted for later analysis.

Exclusion criteria - Patients who are not diabetic; Patients with gestational diabetes; Patients undergoing surgery without a substantive anaesthetic technique, i.e. surgery under local anaesthetic infiltration or topical anaesthesia alone with or without monitored sedation .

Criteria for withdrawal or discontinuation of participants - Due to the observational nature of the study, the protocol does not define any withdrawal/discontinuation criteria. Patients electing to withdraw from the study may do so at any point. In this case, no further data will be collected. Previously collected, encoded data will be anonymised and analysis may be performed up to the point of data collection. Withdrawing participants will not be replaced, provided that their number does not exceed 5% of the projected sample size at the end of the planned recruitment period.

Participant information and informed consent - Written, informed consent, using the approved Informed Consent Form (ICF), will be sought from each patient prior to inclusion unless an explicit, written exemption by the responsible IRB is provided. A Patient Information Leaflet (PIL) will be provided to patients, and must be subject to local IRB review and approval.

End-Points: (Table 1).

Primary end point - Days at Home at 30 days (DAH-30) [12,13]. DAH-30 has been validated as a patient-centric outcome metric by numerous large scale cohort studies [13] as an end-point which is pragmatic and easily obtained. It is affected by both patient factors (poor function, co-morbidities) and surgical technique. DAH-30 is sensitive to surgical risk and impact of post-operative complications in that it accounts for both delayed discharge and re-admission.

Secondary end points –

\*Comprehensive Complications Index (CCI) score, based on Clavien-Dindo scale;[14,15]

\*Quality of Recovery scale (QoR-15), only taken from patients who are in hospital the day after surgery, i.e. Day 1 postoperatively [16],

\*30-day mortality,

\*Length of Stay in Hospital,

\*Length of Stay in ICU if applicable;

\*Incidence of specific major adverse events as listed in European Perioperative Clinical Outcomes Definitions manuscript[17]. These and other outcomes are shown in Table 1.

1  
2  
3  
4 Data sources: The following data will be extracted from clinical charts: age, gender, weight,  
5  
6 height, variables for CCI, variables for SORT calculation (SORT score Appendix 3).

7  
8 ASA classification, relevant medical history, preoperative diabetes medication (substance  
9  
10 classes only), type of anesthesia, date, type, and location of surgery, procedure duration,  
11  
12 date of ICU admission, date of discharge from ICU.

13  
14  
15 A continuous glucose/insulin infusion will be regarded as planned, any insulin boluses on top  
16  
17 of this infusion will be deemed rescue (or “additional”).

18  
19  
20  
21  
22  
23 Bias - In every centre, all diabetic patients undergoing surgery, (except where there is only  
24  
25 conscious sedation, with or without local anaesthetic infiltration or topical anaesthesia to the  
26  
27 eye) are eligible. Centres are invited to enrol their target number of patients (depending on  
28  
29 number of investigators in their team) from date of registration of their centre with ESA for up  
30  
31 to 18 months. Once they start to enroll patients, centres are asked to do so consecutively,  
32  
33 i.e. to take all eligible diabetic patients one after another. No other exclusion criteria apply,  
34  
35 even emergency surgery patients are eligible. Therefore, we do not believe that significant  
36  
37 risk of bias exists.  
38  
39  
40  
41  
42  
43

44 Study procedures:

45  
46 Recruitment and screening -

47  
48 At screening day (“day -90” to “day of surgery”, i.e. within 3 months of planned day of  
49  
50 surgery), patients may be screened and invited to participate. Diabetic patients listed for  
51  
52 both elective and emergency surgery are eligible. They will be offered a Patient Information  
53  
54 Leaflet and the investigator will withdraw to allow the patient to consider it by alone. The  
55  
56 team member will obtain signed written consent if the patient agrees to proceed. While for  
57  
58  
59  
60

1  
2  
3 elective patients, consent may be obtained in a preoperative clinic up to 90 days prior, for  
4  
5 emergency surgery diabetic patients' consent may be requested on the ward, immediately  
6  
7  
8 prior to coming to theatre on the day of surgery. This is justified because there is even less  
9  
10 knowledge currently about the management and outcomes of diabetic patients undergoing  
11  
12 *emergency* surgery, who are acknowledged to be a particularly high-risk group, compared to  
13  
14 diabetic patients undergoing elective surgery. Therefore, including a cohort of these patients  
15  
16 is particularly important to evaluate risk factors for adverse outcomes which may be  
17  
18 mitigated. There is also anecdotal evidence that practice of managing these patients varies  
19  
20 widely between nations and individual centres. The Surgical Outcome Risk Tool (SORT) will  
21  
22 be used to indicate surgical risk [17]  
23  
24  
25  
26  
27  
28  
29

30 If patients remain in hospital on the day after surgery, QoR-15 quality of recovery score will  
31  
32 be documented. Patient data on insulin use, glucose levels and any complications observed  
33  
34 will also be recorded on Day of Discharge, provided patient is discharged within 30 days of  
35  
36 their surgery. At Day 30 after surgery, data will be collected by telephone if the patient has  
37  
38 been discharged. If still in hospital, patient data will be collected on the ward on Day 30. See  
39  
40

41 Figure 1: Study Flow Table  
42  
43  
44  
45  
46  
47  
48

49 Data collection:  
50  
51

52 At the end of the study period, each center will provide an "end of study reporting form" to  
53  
54 report the number of patients meeting the inclusion criteria during the study period and the  
55  
56 total number of screening failure patients. Furthermore, each center will provide a Screening  
57  
58 Failure Tracking Form (Appendix 9) giving the reasons for screening failures at the end of the  
59  
60 study period. Using this form, it will be possible to analyse what are the reasons for exclusion

1  
2  
3 from study (e.g. subject refused to sign informed consent, subject is already participating in  
4 other clinical trial, subject language, cognitive difficulties, etc). Data will be collected at each  
5  
6 other clinical trial, subject language, cognitive difficulties, etc). Data will be collected at each  
7  
8 centre, anonymised, and entered into a bespoke electronic case-report form (eCRF).  
9  
10 Completed forms will be submitted to the sponsor at the ESA Clinical Trials Network (ESA  
11  
12 CTN) in Brussels, Belgium.  
13  
14  
15  
16  
17

## 18 Statistical Analysis Plan

### 19 Primary Outcome

20  
21 Descriptive epidemiology of the perioperative management and postoperative morbidity of  
22  
23 Diabetic patients across different countries in Europe. Morbidity and mortality will be  
24  
25 assessed using Days at Home at 30 days (DAH-30) as the primary outcome.  
26  
27  
28  
29  
30  
31

### 32 Secondary Outcomes

33  
34 Secondary outcomes will be morbidity as assessed by the Comprehensive Complications  
35  
36 Index (CCI) score, based on Clavien-Dindo scale and additional hypotheses of interest as  
37  
38 listed in Table 2.  
39  
40  
41  
42  
43  
44  
45  
46

### 47 Sample size estimation

48  
49 Up to 5% of the population of Europe is thought to have diabetes. About 30 million surgeries  
50  
51 are performed in Europe per annum, therefore perhaps 1.5 million diabetics have surgery in  
52  
53 Europe each year. It is proposed to evaluate a pragmatic sample of 5,000 European diabetic  
54  
55 patients across at least 50 centres in a minimum of 10 nations. It is expected that this should  
56  
57 be sufficient for the main epidemiological aspects of this study. It is envisaged that this target  
58  
59  
60

1  
2  
3 number will be enrolled over a two-year period from initial roll-out, with up to a further 12  
4  
5 months needed for final data acquisition, data cleaning and analysis. A sample size of 5,000  
6  
7 should be sufficient to avoid over-fitting and variance inflation for 50 to 70 factors and  
8  
9 interactions based on the conventional square root or 100 values per variable respectively.  
10  
11 In addition, a sample size of 5,000 will have at least 90% power to find a standardized  
12  
13 difference of 0.15 as significant at  $P < 0.05$  (Bonferroni corrected at  $P < 0.0007$ ) for up to 70  
14  
15 independent hypotheses and in comparing subsets of interest.  
16  
17  
18  
19  
20  
21  
22

### 23 **Primary Statistical Analysis**

24  
25 Descriptive statistics such as mean (SD), median [interquartile range] and frequencies (%)  
26  
27 will be presented as appropriate. Gaussian distributions will be assessed using frequency  
28  
29 histograms, normality plots and the Shapiro-Wilks statistic. The precision of the estimates  
30  
31 will be reported as 95% confidence intervals to show the prevalence and incidence rates of  
32  
33 diabetic phenotypes and major adverse events and complications.  
34  
35

36  
37 Continuous data will be analysed using Student  $t$ , Welch  $t$ , Mann-Whitney  $U$ , one-way  
38  
39 analysis of variance (ANOVA) and Kruskal-Wallis  $H$ -statistics. Categorical data will be  
40  
41 analysed using chi-square independence and expanded Fisher exact statistics. Multiple  
42  
43 hypothesis or comparison testing will be addressed using Tukey-Kramer and Bonferroni  
44  
45 corrections and overall statistical significance will be defined at  $P < 0.05$  (two-sided).  
46  
47

48  
49 Repeated measurements in patients will be analysed using generalized linear mixed models  
50  
51 (GLMM) with maximum likelihood estimation (MLE) using appropriate link functions:  
52  
53 Gaussian, Poisson, Negative Binomial and Logit. Robust multivariable linear, logistic,  
54  
55 proportional hazards and quantile regression models will be constructed to identify  
56  
57 significant independent risk factors for adverse outcomes. Variables with  $P < 0.15$  on bivariate  
58  
59  
60



1  
2  
3 analysis, or that are clinically relevant, will be entered. Multicollinearity will be assessed  
4  
5 using variance inflation factors. Hierarchical nesting of patients in hospitals and countries will  
6  
7 be entered as random effects in multilevel mixed-effects GLMM.  
8  
9

### 10 11 12 13 **Secondary Statistical Analysis**

14  
15 Exploratory post-hoc analyses may be performed to gain further information about the cohort  
16  
17 and to assess clinical outcomes with respect to participating countries and hospitals. Any  
18  
19 post-hoc analyses will be identified as such in any reports. Participating institutions can  
20  
21 request data extraction for further analysis and quality improvement, subject to approval of  
22  
23 the Steering Committee. As the primary purpose of this project is epidemiological, missing  
24  
25 data will not be replaced or imputed.  
26  
27  
28  
29  
30  
31

### 32 **Software**

33  
34 Data will be analysed using Stata 16.1, StataCorp Inc., College Station, TX and Number  
35  
36 Cruncher Statistical Systems 2020 (NCSS), NCSS Inc., Kaysville, UT.  
37  
38  
39  
40  
41

42 The Sponsor and the SC have the right to veto the nesting of a study into MOPED. The  
43  
44 publication of any study nested within MOPED will occur after publication of the main results  
45  
46 of MOPED (main objectives 1 and 2). For transparency, the original paper should be  
47  
48 referenced to in all articles of nested analyses. Authorship rules for potential publications  
49  
50 derived from such nested cohort studies are to be submitted to the Sponsor and SC together  
51  
52 with the study proposal.  
53  
54

55  
56 Requests for data sharing for individual-level meta-analyses are to be addressed to the  
57  
58 Sponsor and SC.  
59  
60

1  
2  
3 The sponsor of the study (ESA CTN) can use anonymised pooled data for internal analyses  
4  
5 and educational purposes.  
6  
7  
8  
9

#### 10 GDPR, Data and Quality Management:

11  
12 Quality control measures will be applied to each stage of data handling to ensure that all  
13 data are reliable and have been processed correctly. This will include written SOP (in  
14 English for all countries) for data collection and entry, automated consistency checks, and  
15 training of National Coordinating Investigator and local PI. It will be the responsibility of the  
16 National Coordinating Investigator, with support by the study coordinating office, to train  
17 local PIs. Local centre coordinators will ensure that the data in the eCRF are carefully  
18 entered and verified regularly. It will be the responsibility of local coordinators to conduct  
19 periodic and random checks to ensure data quality in that centre. The ESA as sponsor is  
20 responsible for securing agreement from all involved parties to ensure direct access to all  
21 trial related sites, and source documents for the purpose of monitoring and auditing. No fee  
22 or financial compensation is given to any co-investigator or participating institution for patient  
23 recruitment.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Data Handling - Data will be entered into a secure on-line database protected by  
45 personalised and confidential usernames and passwords, which document the time and the  
46 individual entering the data. The language of the online database, eCRF, and the relative  
47 SOPs is English and will not be translated into different languages. Data will be collected  
48 directly from source documents into the encoded paper CRF and secondarily entered into  
49 the eCRF. A copy of the original source documents will be stored within a locked  
50 cabinet/office accessible to authorised personnel only in accordance with local and national  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 regulations. All study documents will be archived as required by local legislation. Sponsor  
4  
5 and centres will maintain and update their trial master files according to the recommendation  
6  
7 of the ICH-GCP Guidelines E6(R2).  
8  
9

10  
11  
12 Confidentiality and Data protection - To safeguard patients' confidentiality, a patient  
13  
14 identification code will be assigned to encode data. The confidential log linking patient  
15  
16 identification codes and identifiable patient data will be stored separately in a locked cabinet  
17  
18 accessible to authorised personnel only and corresponding electronic files will be protected  
19  
20 by personalised and confidential usernames and passwords. eCRF are identified through  
21  
22 the patient identification code and will not include any names, initials, date of birth or local  
23  
24 hospital patient numbers. Therefore, no patient identifiable data will be directly accessible  
25  
26 from the eCRF. Open direct access to all relevant trial information as well as source  
27  
28 data/documents will be permitted for purposes of monitoring, audits or inspections by the  
29  
30 sponsor, national coordinators, IRB, or regulatory authorities. All handling of personal data  
31  
32 will comply with the GCP Guidelines and follow strictly the legal and national requirements  
33  
34 for data protection.  
35  
36  
37  
38  
39  
40

41 Patient and Public Involvement – To maximise the benefit of this study to patients, we  
42  
43 prioritised using a patient-centric, holistic primary outcome: Days at Home at 30 days.  
44  
45 Previous Delphi process driven studies have shown this to be a sensitive index of  
46  
47 postoperative complications and their impact on patients' lives. Ireland's diabetes patient  
48  
49 advocacy association, Diabetes Ireland, kindly reviewed the draft protocol and offered  
50  
51 comment and suggestion which influenced the final draft.  
52  
53  
54  
55  
56  
57

58 Publication and dissemination of results:  
59  
60

1  
2  
3 The main results of MOPED and its sub-studies will be published in peer-reviewed  
4 international medical journals and presented at Euroanaesthesia and at international and  
5 national meetings. As recommended by the International Committee of Medical Journal  
6 Editors ([http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-](http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html)  
7 *the-role-of-authors-and-contributors.html*; accessed August 30th 2016), authorship will be  
8 considered based on contributions to recruitment of patients, data acquisition and cleaning,  
9 analysis and interpretation of data, manuscript writing, and submission of national/local  
10 grants. Authors are required to give final approval of the version to be published and agree  
11 to be accountable for all aspects of the work in ensuring that questions related to the  
12 accuracy or integrity of any part of the work are appropriately investigated and resolved. The  
13 Steering Committee (SC) will also be the Writing Committee (WC).

14  
15  
16 All papers derived from the MOPED database will be published under the acronym "The  
17 MOPED Investigators". All authors will be specifically named, in order to give every  
18 investigator the same credit and the same responsibilities for successfully performing this  
19 study. All authors will be mentioned with their name and affiliation in the collaborators list  
20 which will be published in an appendix to the manuscript. The members of the Steering-  
21 Writing committee will be specifically identified as required by most journals. Collaborators  
22 names will be listed in PubMed.

23  
24  
25 It is the responsibility of the local coordinators to determine who is to be considered as  
26 investigator. The local PI will be asked to submit names of staff actively involved from their  
27 institution in the End of Study Reporting Form. If the number of recruited patients from a  
28 centre is too low to justify sufficient active involvement, the SC may decide on the legitimacy

1  
2  
3 of collaboratorship based on other contributions. The final decision will be left to the SC in  
4  
5  
6 consultation with the ESA. The number of investigators allowed from each centre will be  
7  
8 determined by the number of patients enrolled by that centre. No more than 25% of a  
9  
10 centre's enrolled patients should be day cases (ambulatory anaesthesia).  
11  
12  
13

14  
15 Presentation at international meetings will be restricted to members of the SC or their  
16  
17 delegates. National Coordinators will qualify for presentation at national meetings after  
18  
19 approval by the SC and the sponsor. ESA Clinical Trial Network will be acknowledged in all  
20  
21 publications and presentations.  
22  
23  
24

25  
26  
27 After publication of the pooled results, centres will be allowed to use their own anonymised  
28  
29 data for local presentation and publication. Duplicate data publication is not permitted.  
30  
31  
32

33  
34 Contributorship statement:

35  
36 D.B., M.C., J.H., M.H., A.Z. devised the project, D.B., M.C., M.C., J.H., M.H., A.Z.  
37  
38 contributed to the design of the study and developed the protocols for data collection and  
39  
40 analysis. D.B., M.C., M.C., J.H., M.H., R.N., A.Z. were involved in drafting the manuscript. All  
41  
42 authors gave final approval to the publishing of this work. All authors agree to be  
43  
44 accountable for the integrity and veracity of this protocol and the data collected and  
45  
46 analysed thereafter.  
47  
48  
49  
50  
51

52  
53 Competing interests:

54  
55  
56 None declared. No additional data available.  
57  
58  
59  
60

## Funding:

The European Society of Anaesthesiology (ESA) as a study sponsor is providing administrative support for data collating. There is no other funding source for this study.

## References:

1. International diabetes federation, Cho NH, Kirigia J, Claude J et al. IDF diabetes atlas 8<sup>th</sup> ed. 2019: Visit: <http://www.diabetesatlas.org/resources/2017-atlas.html>. [accessed 22 Jan 2020]
2. Frisch A, Chandra P, Smiley D, et al. Prevalence and clinical outcome of hyperglycaemia in the perioperative period in non-cardiac surgery. *Diabetes Care* 2010;33:1783-88.
3. Hulst A, Hermanides J, Hollmann MW, DeVries JH, Preckel B. Lack of Consensus on Peri-Operative Management of Patients with Diabetes Mellitus. *Eur J Anaesthesiol* 2019 Feb;36(2):168-169.
4. Plummer MP, Bellomo R, Cousins CE, et al. Dysglycaemia in the critically ill and the interaction of chronic and acute glycaemia with mortality. *Intensive Care Med.* 2014 Jul;40(7):973-80. doi: 10.1007/s00134-014-3287-7. Epub 2014 Apr 24.
5. Umpierrez G, Smiley D, Jacobs S et al. Randomised study of basal-bolus insulin therapy in the management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). *Diabetes Care* 2011;34:256-61.
6. Emily T Martin 1, Keith S Kaye 2, Caitlin Knott. Diabetes and Risk of Surgical Site Infection: A Systematic Review and Meta-analysis *Infect Control Hosp Epidemiol* 2016 Jan;37(1):88-99. doi: 10.1017/ice.2015.249. Epub 2015 Oct 27.

- 1  
2  
3  
4 7. Vascular events in non-cardiac surgery patients cohort evaluation (VISION  
5  
6 investigators). Association between complications and death within 30 days after  
7  
8 noncardiac surgery. CMAJ 2019;191:E830-37.  
9
- 10  
11 8. Kuzulugil D, Papeix G, Luu J, Kerridge R. Recent advances in diabetes treatments and  
12  
13 their perioperative implications. Current Opinion in Anaesthesiology 2019;32:398-404.  
14
- 15  
16 9. National Confidential Enquiry into Patient Outcome and Death. Highs and Lows, London,  
17  
18 2018. Visit:  
19  
20 [https://www.ncepod.org.uk/2018pd/Highs%and%20Lows\\_Summary%20Report.pdf](https://www.ncepod.org.uk/2018pd/Highs%and%20Lows_Summary%20Report.pdf).  
21  
22 Accessed 22 January 2020  
23
- 24  
25 10. Garg R, Schuman B, Bader A et al. Effect of preoperative diabetes management on  
26  
27 glycaemic control and clinical outcomes after elective surgery. Ann Surg 2018;267:858-  
28  
29 62.  
30
- 31  
32 11. Giuseppe Gatti 1, Andrea Perrotti, Daniel Reichart. Glycated Hemoglobin and Risk of  
33  
34 Sternal Wound Infection After Isolated Coronary Surgery. Circ J 2016 Dec 22;81(1):36-  
35  
36 43.doi: 10.1253/circj.CJ-16-0778.  
37
- 38  
39 12. Bell M, Erikson L, Svensson T et al. Days at home after surgery: an integrated and  
40  
41 efficient outcome measure for clinical trials and quality assurance. E-Clinical  
42  
43 Medicine 2019;11:18-26.  
44
- 45  
46 13. Myles PS, Shulman M, Heritier S et al. Validation of days at home as an outcome  
47  
48 measure after surgery: A prospective cohort study. BMJ Open 2017;7:E015828  
49
- 50  
51 14. Slankamenac K, Nederlof N, Pessaux P, et al. The comprehensive complications index:  
52  
53 a novel and more sensitive endpoint for assessing outcome and reducing sample size in  
54  
55 randomized controlled trials. Ann Surg 2014; 260(5):757-62; discussion 762-3.  
56  
57  
58  
59  
60

- 1  
2  
3  
4 15. Clavien PA, Vetter D, Staiger RD, et al. The Comprehensive Complication Index  
5  
6 (CCI(R)): Added Value and Clinical Perspectives 3 Years "Down the Line". *Ann Surg*  
7  
8 2017; 265(6):1045-1050.  
9
- 10  
11 16. Stark PA, Myles PS, Burke JA. Development and Psychometric Evaluation of a  
12  
13 Postoperative Quality of Recovery Score. The QoR-15. *Anesthesiology*  
14  
15 2013;118(6):1332-40.  
16
- 17  
18 17. Protopappa KL, Simpson JC, Smith N, Moonesinghe R. Development and validation of  
19  
20 the surgical outcome risk tool (SORT). *Br J Surg* 2014;101:1774-83.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Figure Legend:

**Figure 1: Study work flow**

**Table 1: Study end-points**


| Primary                    | Secondary                                     | Tertiary  |
|----------------------------|---|---|
| Days at Home<br>at 30 days | Comprehensive Complications<br>Index          | Time to resumption of normal<br>diabetes therapy                |
|                            | Quality of Recovery scale (QoR-15)            | Incidence of diabetic ketoacidosis<br>or hypoglycaemia          |
|                            | 30-day mortality                              | incidence and duration of use of<br>IV insulin infusion therapy |
|                            | Length of Stay in Hospital                    | Incidence of diabetic ketoacidosis<br>or hypoglycaemia          |
|                            | Length of Stay in ICU (if applicable)         | Change in diabetic management<br>at 30 days                     |
|                            | Incidence of specific major adverse<br>events |   |

**Table 2. Secondary outcomes and hypotheses of interest**

| Hypothesis   | Variables   |
|--|---|
| There are major differences in perioperative management of diabetic patients in different nations in Europe  | Insulin dose<br>Methods of insulin admin<br>Oral hypoglycaemic use                |
| There are major differences in postoperative morbidity and outcomes among diabetic patients in different nations in Europe   | DAH-30<br>CCI   |
| Outcomes among patients with different strata of glycaemic control, i.e.<br>HbA1c <53,<br>HbA1c 53-69 and<br>HbA1c >69 mmol.mmol will be different;  | Preop HbA1c and glucose<br>DAH-30<br>CCI  |
| Diabetic patient outcomes differ depending on anaesthetic technique:<br><br>Volatile versus total intravenous anaesthesia;<br><br>Regional versus general anaesthesia (GA)<br><br>Combined GA and regional anaesthesia versus patients receiving GA alone. | DAH30<br>CCI<br>All secondary outcomes  |
| Diabetic Patients receiving liberal fluids perioperatively have better outcomes than patients receiving restrictive fluids, compared to their body weight  | DAH-30, CCI<br>crystalloid and colloid totals up to PACU                          |
| Type 2 DM patients have worse outcomes than Type 1   | DAH-30, CCI   |
| Patients where a consultant /senior surgeon and senior anaesthesiologist is present have better outcomes than when not present   | Personnel tracking<br>All Outcomes  |
| Diabetic patients of longer duration experience more hypotension duration/episodes due to autonomic neuropathy and have worse outcomes than diabetic patients with shorter duration  | Intraop and PACU hypotension and use vasopressors and outcomes;<br>Duration of DM |

|   |   |
|---|---|
| NSAID use perioperatively worsens outcomes especially AKI   | DAH30,CCI<br>AKI  |
| Risk factors for higher morbidity in diabetic patients undergoing surgery   | All factors,<br>All outcomes<br>Multivariable analysis    |
| Patients with preoperative GLP-1 use have better perioperative glucose control (and outcome) as compared to other oral hypoglycaemics | PreOp medication use DAH30<br>CCI                         |
| There is no association between metformin use and perioperative lactic acidosis   | Preop medication use<br>Incidence of DKA<br>DAH-30<br>CCI |
| Patients with known preoperative susceptibility for hypoglycaemia/DKA are more prone for perioperative hypoglycaemia/DKA              | PreOK hypoglycaemia/DKA<br>PeriOK hypoglycaemia/DKA       |
| Surgery in DM will lead to dysglycaemia up to 30 days   | DM medication at 30 days                                  |

Figure 1: Study Work Flow



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

|                              | Item No | Recommendation  |
|------------------------------|---------|---|
| <b>Title and abstract</b>    | 1       | (a) Indicate the study's design with a commonly used term in the title or the abstract<br>(b) Provide in the abstract an informative and balanced summary of what was done and what was found   |
| <b>Introduction</b>          |         |   |
| Background/rationale         | 2       | Explain the scientific background and rationale for the investigation being reported  |
| Objectives                   | 3       | State specific objectives, including any prespecified hypotheses  |
| <b>Methods</b>               |         |   |
| Study design                 | 4       | Present key elements of study design early in the paper   |
| Setting                      | 5       | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection   |
| Participants                 | 6       | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br>(b) For matched studies, give matching criteria and number of exposed and unexposed   |
| Variables                    | 7       | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable  |
| Data sources/<br>measurement | 8*      | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group  |
| Bias                         | 9       | Describe any efforts to address potential sources of bias   |
| Study size                   | 10      | Explain how the study size was arrived at   |
| Quantitative variables       | 11      | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why  |
| Statistical methods          | 12      | (a) Describe all statistical methods, including those used to control for confounding<br>(b) Describe any methods used to examine subgroups and interactions<br>(c) Explain how missing data were addressed<br>(d) If applicable, explain how loss to follow-up was addressed<br>(e) Describe any sensitivity analyses  |
| <b>Results</b>               |         |   |
| Participants                 | 13*     | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed<br>(b) Give reasons for non-participation at each stage<br>(c) Consider use of a flow diagram   |
| Descriptive data             | 14*     | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders<br>(b) Indicate number of participants with missing data for each variable of interest<br>(c) Summarise follow-up time (eg, average and total amount)  |
| Outcome data                 | 15*     | Report numbers of outcome events or summary measures over time  |
| Main results                 | 16      | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included<br>(b) Report category boundaries when continuous variables were categorized<br>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |

|    |                          |    |  |
|----|--------------------------|----|--|
| 1  | Other analyses           | 17 | Report other analyses done—eg analyses of subgroups and interactions, and              |
| 2  |                          |    | sensitivity analyses   |
| 3  | <hr/>                    |    |  |
| 4  | <b>Discussion</b>        |    |  |
| 5  | Key results              | 18 | Summarise key results with reference to study objectives                               |
| 6  | Limitations              | 19 | Discuss limitations of the study, taking into account sources of potential bias or     |
| 7  |                          |    | imprecision. Discuss both direction and magnitude of any potential bias                |
| 8  | <hr/>                    |    |  |
| 9  | Interpretation           | 20 | Give a cautious overall interpretation of results considering objectives, limitations, |
| 10 |                          |    | multiplicity of analyses, results from similar studies, and other relevant evidence    |
| 11 | <hr/>                    |    |  |
| 12 | Generalisability         | 21 | Discuss the generalisability (external validity) of the study results                  |
| 13 | <hr/>                    |    |  |
| 13 | <b>Other information</b> |    |  |
| 14 | Funding                  | 22 | Give the source of funding and the role of the funders for the present study and, if   |
| 15 |                          |    | applicable, for the original study on which the present article is based               |
| 16 | <hr/>                    |    |  |

17  
18 \*Give information separately for exposed and unexposed groups.

19  
20  
21 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and  
22 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely  
23 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
24 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
25 available at <http://www.strobe-statement.org>.

# BMJ Open

## Protocol for a prospective, international cohort study on the Management and Outcomes of Perioperative Care among European Diabetic Patients (MOPED)

|                                 |   |
|---------------------------------|---|
| Journal:                        | <i>BMJ Open</i>   |
| Manuscript ID                   | bmjopen-2020-044394.R2  |
| Article Type:                   | Protocol  |
| Date Submitted by the Author:   | 18-May-2021   |
| Complete List of Authors:       | buggy , Donal; University College Dublin, ; Nolan, Rachel; Mater Misericordiae University Hospital, Anaesthesia Coburn, Mark; Medical Faculty, RWTH Aachen, Anesthesiology Columb, Malachy; Manchester University NHS Foundation Trust, Wythenshawe Hospital Acute Intensive Care Unit Hermanides, Jeroen; Amsterdam University Medical Centres, Department of Anesthesiology Hollman, M; AMC, Zarbock, Alexander; Universität Münster, |
| <b>Primary Subject Heading</b>: | Anaesthesia   |
| Secondary Subject Heading:      | Diabetes and endocrinology, Surgery   |
| Keywords:                       | Adult anaesthesia < ANAESTHETICS, DIABETES & ENDOCRINOLOGY, SURGERY   |
|                                 |   |

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Title:

**Protocol for a prospective, international cohort study on the Management and Outcomes of Perioperative Care among European Diabetic Patients (MOPED)**

Donal J. Buggy,<sup>1,6</sup> Rachel Nolan<sup>1</sup>, Mark Coburn,<sup>2</sup> Malachy Columb,<sup>3</sup> Jeroen Hermanides,<sup>4</sup> Markus W. Hollmann,<sup>4</sup> Alexander Zarbock.<sup>5</sup>

<sup>1</sup>Department of Anaesthesiology and Perioperative Medicine, Mater University Hospital, School of Medicine, University College Dublin, Ireland;

<sup>2</sup>Department of Anaesthesiology and Perioperative Medicine, University of Bonn, Germany;

<sup>3</sup>Department of Anaesthesiology and Intensive Medicine, Manchester University Hospitals Foundation NHS Trust, Wythenshawe, United Kingdom;

<sup>4</sup>Department of Anesthesiology , Amsterdam University Medical Centers, location AMC, Amsterdam, Netherlands;

<sup>5</sup>Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, Germany.

<sup>6</sup>Collaborator, Outcomes Research Consortium, Cleveland Clinic, OH, USA.

Corresponding author:

Donal J Buggy donal.buggy@ucd.ie

Funding:

MOPED is sponsored by a grant from the European Society of Anaesthesiology Clinical Trial Network (ESA CTN).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 Author Contributions:  
4

5  
6 DJB: Concept instigation, ESA funding applicant, study design, manuscript draft;  
7

8 Malachy Colomb: : Study design, analysis plan draft;  
9

10 Marc Coburn: Study design, manuscript draft;  
11

12  
13 JH: Study design, manuscript draft;  
14

15 MWH: Study design, manuscript draft;  
16

17  
18 RN: Study design, manuscript draft;  
19

20 AZ: Study design, manuscript draft;  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract:**

**Introduction:** Diabetes is common (about 20m patients in Europe), and diabetic patients have more surgical interventions than the general population. There are plausible pathophysiological and clinical mechanisms suggesting that diabetic patients are at increased risk of postoperative complications. When postoperative complications occur in the general population, they increase major adverse events and subsequently increase one-year mortality. This is likely to be worse in diabetic patients. There is variation in practice guidelines in different countries in the perioperative management of diabetic patients undergoing major surgery, and whether this may affect postoperative outcome has not been investigated on a large scale. Neither is it known whether different strata of preoperative glycaemic control affects outcome.

**Methods and analysis:** A prospective, observational, international, multicentre cohort study, recruiting 5,000 diabetic patients undergoing elective or emergency surgery in at least n=50 centres (NCT04511312). Inclusion criteria are any diabetic patient undergoing surgery under any substantive anaesthetic technique. Exclusion criteria are not being a confirmed diabetic patient and diabetic patients undergoing procedures under monitored sedation or local anaesthetic infiltration only. Follow up duration is 30 days after surgery. Primary outcome is Days At Home at 30 days (DAH-30). Secondary outcomes are Comprehensive Complications Index (CCI), Quality of Recovery (QoR-15) Day 1, 30 -day mortality, length of hospital stay and incidence of specific major adverse events (MI, MINS, AKI, PPC, CVA, PE, DVT, Surgical Site Infection (SSI), Postoperative pulmonary infection (PPI)). Tertiary outcomes include time to resumption of normal diabetes therapy, incidence of diabetic

1  
2  
3 ketoacidosis or hypoglycaemia, incidence and duration of use of IV insulin infusion therapy,  
4  
5  
6 and change in diabetic management at 30 days.  
7  
8  
9

10 **Ethics and dissemination:** This study will adhere to the principles of the Declaration of  
11  
12 Helsinki (amendment 2013) by the World Medical Association and the ICH-GCP Guidelines  
13  
14 E6(R2). Specific national and local regulatory authority requirements will be followed as  
15  
16 applicable. The main results of MOPED and its sub-studies will be published in peer-  
17  
18 reviewed international medical journals and presented at Euroanaesthesia congress and  
19  
20 other international and national meetings.  
21  
22  
23  
24

25 ClinicalTrials.gov Identifier: NCT04511312  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ARTICLE SUMMARY

### Strengths and limitations of this study:

1. This will be the largest prospective, observational study of the perioperative anaesthetic management of diabetic patients, documenting the influence of perioperative management on 30-day outcomes.
2. The primary endpoint is Days at Home at 30 days (DAH-30), which is a recently validated standardised end-point for perioperative trials (range 0-30 days, higher number indicating better outcome) that gives a patient-centred outcome reflecting mortality, postoperative complications and return to independent living.
3. Secondary outcomes include Comprehensive Complications Index (CCI), a scale 0-100, higher number indicating worse outcome), based on the Clavien-Dindo scale of postoperative complications.
4. Broad inclusion criteria includes confirmed diabetic patients undergoing any surgery under any substantive anaesthetic technique, which will enhance the external validity of the trial results and render it generalisable on a global scale.
5. The power of this study is driven by the target number 5,000 patients, which will enable more than 60 variables to be evaluated and up to eleven a priori hypotheses to be tested.

**Keywords:** Diabetes, perioperative, complications, glycaemic control

**Word Count:** 3,146

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

**Introduction:**

The incidence of diabetes is increasing globally, with an estimated 20 m diabetic patients in Europe. This is likely to increase, adding to societal demands on European health services.[1] Diabetic patients are more likely to have surgical interventions than the general population.[2] There are plausible pathophysiological and clinical mechanisms that diabetic patients are at increased risk of postoperative complications.[3,4] When postoperative complications occur in the general population, they increase mortality or risk of major adverse cardiovascular events (Myocardial Infarction, Cerebrovascular Accident, Pulmonary embolism) at 30-days and up to one year later.[5-7] In addition, diabetes is an independent risk factor for surgical site infections [6].

National bodies in Europe and elsewhere differ in their guidelines on management of diabetic patients undergoing surgery and small observational studies confirm wide variability in practice and perioperative management between centres.[3,8] Given the multiplicity of guidelines and differing recommendations, it is unsurprising that variability of 'real-world' clinical practice regarding perioperative management of oral antihyperglycemic medications and insulin therapy has been observed in audits such as the National Confidential Enquiry into Patient Outcome and Death (NCEPOD).[9] Whether this variability in practice affects postoperative outcome among diabetic patients in Europe or elsewhere has not been investigated.

Further, although it is assumed that diabetic patients are at increased risk of postoperative complications[5-8], this has not been evaluated recently, especially in light of ongoing developments in perioperative care, such as Enhanced Recovery Programmes.[7] While a



1  
2  
3 quality improvement intervention study has shown that maintaining tight preoperative  
4 glycaemic control improves postoperative glycaemic control[10], it is not known if this  
5  
6 reduces postoperative morbidity overall. Moreover, whether certain anaesthetic techniques  
7  
8 may be associated with better or worse outcomes after major non-cardiac surgery is  
9  
10  
11  
12  
13 unknown.

14  
15  
16  
17  
18 Sub-group analysis will provide novel data on how patients with different strata (levels) of  
19  
20 preoperative glycaemic control progress in the postoperative period. Poor pre-operative  
21  
22 glycaemic control is associated with postoperative complications in retrospective  
23  
24 studies[10,11]. If this prospective study confirms an association between the level of  
25  
26 preoperative glycaemic control and postoperative outcome, then the beginning of  
27  
28 personalised perioperative medicine for diabetic patients might be enabled. For example, it  
29  
30 is known from intensive care medicine that patients with better pre-admission glycaemic  
31  
32 control (HbA1c < 53 mmol.mol) have worse outcomes if they develop hyperglycaemia,  
33  
34 compared with patients whose pre-existing glycaemic control was already poor (HbA1c > 69  
35  
36 mmol.mol) [4,11].  
37  
38  
39  
40  
41  
42  
43

44 This large, multicentre, international, prospective observational study will address these  
45  
46 urgent research questions and will inform better management and outcomes for patients  
47  
48 undergoing surgery with this high risk, highly prevalent condition, which is increasing in  
49  
50 incidence in the European population.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Objectives –  
4

5  
6 To address the following research questions:  
7

8  
9  
10 1. What is the epidemiology of diabetic patients undergoing surgery across Europe: Are  
11  
12 there major variations in perioperative glycaemic control? Does management practice vary  
13  
14 between nations?  
15

16  
17 2. What is the extent and patient-centred impact of postoperative complications among  
18  
19 diabetic patients up to 30 days after surgery in Europe?  
20  
21

22 3. To undertake sub-group analysis comparing:  
23

24 a. Type 1, Type 2, and other diabetic patients;  
25

26 b. Patients with different strata (levels) of glycaemic control, i.e. HbA1c <53, HbA1c  
27  
28 53-69 and HbA1c >69 mmol.mol;  
29

30  
31 c. Patients who received different anaesthetic techniques: -Volatile versus total  
32  
33 intravenous anaesthesia; regional versus general anaesthesia (GA);  
34

35  
36 d. Whether diabetic patients of longer duration versus more recently diagnosed  
37  
38 diabetic patients have higher risk of intraoperative hypotension due to autonomic  
39  
40 neuropathy.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

#### Methods and Analysis:

Overall study design - MOPED is a prospective, observational, international, multicentre cohort study, supported by the European Society of Anaesthesiology (ESA). It has been registered on [clinicaltrials.gov](https://clinicaltrials.gov), NCT04511312.

Setting - Any hospital in Europe (as defined by the World Health Organisation) is welcome to participate as a study centre. Non-European centres may be accepted upon request to the Steering Committee. Centres will be asked to enroll a minimum of 45 patients, in order to nominate one named co-investigator. The recruitment period will be up to 18 months from the date of the centre's registration with ESA. No more than one quarter (25%) of a centre's patients can be day cases (ambulatory anaesthesia). Study centre registration will occur online via the dedicated "Call for Centres form" on the ESA website. The start of recruitment for individual centres should be soon as possible after centre registration with ESA, provided that there is prior Institutional Review Board (IRB) approval. It is envisaged that at least n=50 centres will actively enroll patients. It is hoped that patients from at least ten nations will be enrolled. Enrollment will continue until the planned sample size (n=5,000) has been reached.

National coordinating investigators are anaesthesiologists appointed by ESA and the Steering Committee to lead the project within individual countries. Their responsibility includes:

Identifying participating centres in their country and recruiting local co-ordinators in participating hospitals; Ensuring all necessary national or regional regulatory approvals are in place prior to start of patient inclusion; facilitating good communication between ESA headquarters and the participating sites in that nation. Local centre co-ordinators may be

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

anesthesiologists, surgeons or diabetes physician working in perioperative medicine who will ensure all relevant regulatory/ethical approvals are in place for their institution, and who will supervise enrollment, data collection and adjudicate morbidity events.

#### Participants:

Inclusion criteria - Diabetic patients (all classes except gestational diabetes) undergoing surgery with a substantive anaesthetic technique will be included. A substantive anaesthetic technique is defined as one requiring any general anaesthesia or any specific regional anaesthetic technique or a combination. Ambulatory, elective or emergency surgery and patients who receive postoperative care in intensive care or high dependency units will be included. Pre-defined subgroups of diabetic patients will be highlighted for later analysis.

Exclusion criteria - Patients who are not diabetic; Patients with gestational diabetes; Patients undergoing surgery without a substantive anaesthetic technique, i.e. surgery under local anaesthetic infiltration or topical anaesthesia alone with or without monitored sedation .

Criteria for withdrawal or discontinuation of participants - Due to the observational nature of the study, the protocol does not define any withdrawal/discontinuation criteria. Patients electing to withdraw from the study may do so at any point. In this case, no further data will be collected. Previously collected, encoded data will be anonymised and analysis may be performed up to the point of data collection. Withdrawing participants will not be replaced, provided that their number does not exceed 5% of the projected sample size at the end of the planned recruitment period.

1  
2  
3 Participant information and informed consent - Written, informed consent, using the  
4  
5 approved Informed Consent Form (ICF), will be sought from each patient prior to inclusion  
6  
7 unless an explicit, written exemption by the responsible IRB is provided. A Patient  
8  
9 Information Leaflet (PIL) will be provided to patients, and must be subject to local IRB  
10  
11 review and approval.  
12  
13  
14  
15  
16  
17

18 End-Points: (Table 1).  
19

20 Primary end point - Days at Home at 30 days (DAH-30) [12,13]. DAH-30 has been validated  
21  
22 as a patient-centric outcome metric by numerous large scale cohort studies [13] as an  
23  
24 end-point which is pragmatic and easily obtained. It is affected by both patient factors  
25  
26 (poor function, co-morbidities) and surgical technique. DAH-30 is sensitive to surgical risk  
27  
28 and impact of post-operative complications in that it accounts for both delayed discharge  
29  
30 and re-admission.  
31  
32  
33

34 Secondary end points –  
35

36 \*Comprehensive Complications Index (CCI) score, based on Clavien-Dindo scale;[14,15]  
37

38 \*Quality of Recovery scale (QoR-15), only taken from patients who are in hospital the day  
39  
40 after surgery, i.e. Day 1 postoperatively [16],  
41  
42

43 \*30-day mortality,  
44  
45

46 \*Length of Stay in Hospital,  
47  
48

49 \*Length of Stay in ICU if applicable;  
50  
51

52 \*Incidence of specific major adverse events as listed in European Perioperative Clinical  
53  
54 Outcomes Definitions manuscript[17]. These and other outcomes are shown in Table 1.  
55  
56  
57  
58  
59  
60

1  
2  
3 Data sources: The following data will be extracted from clinical charts: age, gender, weight,  
4 height, variables for CCI, variables for SORT calculation (SORT score Appendix 3).

5  
6  
7  
8 ASA classification, relevant medical history, preoperative diabetes medication (substance  
9 classes only), type of anesthesia, date, type, and location of surgery, procedure duration,  
10 date of ICU admission, date of discharge from ICU.  
11  
12

13  
14  
15 A continuous glucose/insulin infusion will be regarded as planned, any insulin boluses on top  
16 of this infusion will be deemed rescue (or “additional”).  
17  
18

19  
20  
21  
22 Bias - In every centre, all diabetic patients undergoing surgery, (except where there is only  
23 conscious sedation, with or without local anaesthetic infiltration or topical anaesthesia to the  
24 eye) are eligible. Centres are invited to enrol their target number of patients (depending on  
25 number of investigators in their team) from date of registration of their centre with ESA for up  
26 to 18 months. Once they start to enroll patients, centres are asked to do so consecutively,  
27 i.e. to take all eligible diabetic patients one after another. No other exclusion criteria apply,  
28 even emergency surgery patients are eligible. Therefore, we do not believe that significant  
29 risk of bias exists.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Study procedures:

45  
46 Recruitment and screening -

47  
48 At screening day (“day -90” to “day of surgery”, i.e. within 3 months of planned day of  
49 surgery), patients may be screened and invited to participate. Diabetic patients listed for  
50 both elective and emergency surgery are eligible. They will be offered a Patient Information  
51 Leaflet and the investigator will withdraw to allow the patient to consider it by alone. The  
52 team member will obtain signed written consent if the patient agrees to proceed. While for  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 elective patients, consent may be obtained in a preoperative clinic up to 90 days prior, for  
5  
6 emergency surgery diabetic patients' consent may be requested on the ward, immediately  
7  
8 prior to coming to theatre on the day of surgery. This is justified because there is even less  
9  
10 knowledge currently about the management and outcomes of diabetic patients undergoing  
11  
12 *emergency* surgery, who are acknowledged to be a particularly high-risk group, compared to  
13  
14 diabetic patients undergoing elective surgery. Therefore, including a cohort of these patients  
15  
16 is particularly important to evaluate risk factors for adverse outcomes which may be  
17  
18 mitigated. There is also anecdotal evidence that practice of managing these patients varies  
19  
20 widely between nations and individual centres. The Surgical Outcome Risk Tool (SORT) will  
21  
22 be used to indicate surgical risk [17]  
23  
24  
25  
26  
27  
28  
29

30 If patients remain in hospital on the day after surgery, QoR-15 quality of recovery score will  
31  
32 be documented. Patient data on insulin use, glucose levels and any complications observed  
33  
34 will also be recorded on Day of Discharge, provided patient is discharged within 30 days of  
35  
36 their surgery. At Day 30 after surgery, data will be collected by telephone if the patient has  
37  
38 been discharged. If still in hospital, patient data will be collected on the ward on Day 30. See  
39  
40

41 Figure 1: Study Flow Table  
42  
43  
44  
45  
46  
47

48 Data collection:

49 At the end of the study period, each center will provide an "end of study reporting form" to  
50  
51 report the number of patients meeting the inclusion criteria during the study period and the  
52  
53 total number of screening failure patients. Furthermore, each center will provide a Screening  
54  
55 Failure Tracking Form (Appendix 9) giving the reasons for screening failures at the end of the  
56  
57 study period. Using this form, it will be possible to analyse what are the reasons for exclusion  
58  
59  
60

1  
2  
3 from study (e.g. subject refused to sign informed consent, subject is already participating in  
4 other clinical trial, subject language, cognitive difficulties, etc). Data will be collected at each  
5  
6 other clinical trial, subject language, cognitive difficulties, etc). Data will be collected at each  
7  
8 centre, anonymised, and entered into a bespoke electronic case-report form (eCRF).  
9  
10 Completed forms will be submitted to the sponsor at the ESA Clinical Trials Network (ESA  
11  
12 CTN) in Brussels, Belgium.  
13  
14  
15  
16  
17

## 18 Statistical Analysis Plan

### 19 Primary Outcome

20  
21 Descriptive epidemiology of the perioperative management and postoperative morbidity of  
22  
23 Diabetic patients across different countries in Europe. Morbidity and mortality will be  
24  
25 assessed using Days at Home at 30 days (DAH-30) as the primary outcome.  
26  
27  
28  
29  
30  
31

### 32 Secondary Outcomes

33  
34 Secondary outcomes will be morbidity as assessed by the Comprehensive Complications  
35  
36 Index (CCI) score, based on Clavien-Dindo scale and additional hypotheses of interest as  
37  
38 listed in Table 2.  
39  
40  
41  
42  
43  
44  
45  
46

### 47 Sample size estimation

48  
49 Up to 5% of the population of Europe is thought to have diabetes. About 30 million surgeries  
50  
51 are performed in Europe per annum, therefore perhaps 1.5 million diabetics have surgery in  
52  
53 Europe each year. It is proposed to evaluate a pragmatic sample of 5,000 European diabetic  
54  
55 patients across at least 50 centres in a minimum of 10 nations. It is expected that this should  
56  
57 be sufficient for the main epidemiological aspects of this study. It is envisaged that this target  
58  
59  
60



1  
2  
3 number will be enrolled over a two-year period from initial roll-out, with up to a further 12  
4  
5 months needed for final data acquisition, data cleaning and analysis. A sample size of 5,000  
6  
7 should be sufficient to avoid over-fitting and variance inflation for 50 to 70 factors and  
8  
9 interactions based on the conventional square root or 100 values per variable respectively.  
10  
11 In addition, a sample size of 5,000 will have at least 90% power to find a standardized  
12  
13 difference of 0.15 as significant at  $P < 0.05$  (Bonferroni corrected at  $P < 0.0007$ ) for up to 70  
14  
15 independent hypotheses and in comparing subsets of interest.  
16  
17  
18  
19  
20  
21  
22

### 23 **Primary Statistical Analysis**

24  
25 Descriptive statistics such as mean (SD), median [interquartile range] and frequencies (%)  
26  
27 will be presented as appropriate. Gaussian distributions will be assessed using frequency  
28  
29 histograms, normality plots and the Shapiro-Wilks statistic. The precision of the estimates  
30  
31 will be reported as 95% confidence intervals to show the prevalence and incidence rates of  
32  
33 diabetic phenotypes and major adverse events and complications.  
34  
35

36  
37 Continuous data will be analysed using Student  $t$ , Welch  $t$ , Mann-Whitney  $U$ , one-way  
38  
39 analysis of variance (ANOVA) and Kruskal-Wallis  $H$ -statistics. Categorical data will be  
40  
41 analysed using chi-square independence and expanded Fisher exact statistics. Multiple  
42  
43 hypothesis or comparison testing will be addressed using Tukey-Kramer and Bonferroni  
44  
45 corrections and overall statistical significance will be defined at  $P < 0.05$  (two-sided).  
46  
47

48  
49 Repeated measurements in patients will be analysed using generalized linear mixed models  
50  
51 (GLMM) with maximum likelihood estimation (MLE) using appropriate link functions:  
52  
53 Gaussian, Poisson, Negative Binomial and Logit. Robust multivariable linear, logistic,  
54  
55 proportional hazards and quantile regression models will be constructed to identify  
56  
57 significant independent risk factors for adverse outcomes. Variables with  $P < 0.15$  on bivariate  
58  
59  
60

1  
2  
3 analysis, or that are clinically relevant, will be entered. Multicollinearity will be assessed  
4  
5 using variance inflation factors. Hierarchical nesting of patients in hospitals and countries will  
6  
7 be entered as random effects in multilevel mixed-effects GLMM.  
8  
9

### 10 11 12 13 **Secondary Statistical Analysis**

14  
15 Exploratory post-hoc analyses may be performed to gain further information about the cohort  
16  
17 and to assess clinical outcomes with respect to participating countries and hospitals. Any  
18  
19 post-hoc analyses will be identified as such in any reports. Participating institutions can  
20  
21 request data extraction for further analysis and quality improvement, subject to approval of  
22  
23 the Steering Committee. As the primary purpose of this project is epidemiological, missing  
24  
25 data will not be replaced or imputed.  
26  
27  
28  
29  
30  
31

### 32 **Software**

33  
34 Data will be analysed using Stata 16.1, StataCorp Inc., College Station, TX and Number  
35  
36 Cruncher Statistical Systems 2020 (NCSS), NCSS Inc., Kaysville, UT.  
37  
38  
39  
40  
41

42 The Sponsor and the SC have the right to veto the nesting of a study into MOPED. The  
43  
44 publication of any study nested within MOPED will occur after publication of the main results  
45  
46 of MOPED (main objectives 1 and 2). For transparency, the original paper should be  
47  
48 referenced to in all articles of nested analyses. Authorship rules for potential publications  
49  
50 derived from such nested cohort studies are to be submitted to the Sponsor and SC together  
51  
52 with the study proposal.  
53  
54

55  
56 Requests for data sharing for individual-level meta-analyses are to be addressed to the  
57  
58 Sponsor and SC.  
59  
60

1  
2  
3 The sponsor of the study (ESA CTN) can use anonymised pooled data for internal analyses  
4  
5 and educational purposes.  
6  
7  
8  
9

#### 10 GDPR, Data and Quality Management:

11  
12 Quality control measures will be applied to each stage of data handling to ensure that all  
13 data are reliable and have been processed correctly. This will include written SOP (in  
14 English for all countries) for data collection and entry, automated consistency checks, and  
15 training of National Coordinating Investigator and local PI. It will be the responsibility of the  
16 National Coordinating Investigator, with support by the study coordinating office, to train  
17 local PIs. Local centre coordinators will ensure that the data in the eCRF are carefully  
18 entered and verified regularly. It will be the responsibility of local coordinators to conduct  
19 periodic and random checks to ensure data quality in that centre. The ESA as sponsor is  
20 responsible for securing agreement from all involved parties to ensure direct access to all  
21 trial related sites, and source documents for the purpose of monitoring and auditing. No fee  
22 or financial compensation is given to any co-investigator or participating institution for patient  
23 recruitment.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Data Handling - Data will be entered into a secure on-line database protected by  
45 personalised and confidential usernames and passwords, which document the time and the  
46 individual entering the data. The language of the online database, eCRF, and the relative  
47 SOPs is English and will not be translated into different languages. Data will be collected  
48 directly from source documents into the encoded paper CRF and secondarily entered into  
49 the eCRF. A copy of the original source documents will be stored within a locked  
50 cabinet/office accessible to authorised personnel only in accordance with local and national  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 regulations. All study documents will be archived as required by local legislation. Sponsor  
4  
5 and centres will maintain and update their trial master files according to the recommendation  
6  
7 of the ICH-GCP Guidelines E6(R2).  
8  
9

10  
11  
12  
13 Confidentiality and Data protection - To safeguard patients' confidentiality, a patient  
14  
15 identification code will be assigned to encode data. The confidential log linking patient  
16  
17 identification codes and identifiable patient data will be stored separately in a locked cabinet  
18  
19 accessible to authorised personnel only and corresponding electronic files will be protected  
20  
21 by personalised and confidential usernames and passwords. eCRF are identified through  
22  
23 the patient identification code and will not include any names, initials, date of birth or local  
24  
25 hospital patient numbers. Therefore, no patient identifiable data will be directly accessible  
26  
27 from the eCRF. Open direct access to all relevant trial information as well as source  
28  
29 data/documents will be permitted for purposes of monitoring, audits or inspections by the  
30  
31 sponsor, national coordinators, IRB, or regulatory authorities. All handling of personal data  
32  
33 will comply with the GCP Guidelines and follow strictly the legal and national requirements  
34  
35 for data protection.  
36  
37  
38  
39

40  
41 Patient and Public Involvement – To maximise the benefit of this study to patients, we  
42  
43 prioritised using a patient-centric, holistic primary outcome: Days at Home at 30 days.  
44  
45 Previous Delphi process driven studies have shown this to be a sensitive index of  
46  
47 postoperative complications and their impact on patients' lives. Ireland's diabetes patient  
48  
49 advocacy association, Diabetes Ireland, kindly reviewed the draft protocol and offered  
50  
51 comment and suggestion which influenced the final draft.  
52  
53  
54

55  
56  
57  
58 Publication and dissemination of results:  
59  
60

1  
2  
3  
4 The main results of MOPED and its sub-studies will be published in peer-reviewed  
5  
6 international medical journals and presented at Euroanaesthesia and at international and  
7  
8 national meetings. As recommended by the International Committee of Medical Journal  
9  
10 Editors ([http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-](http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html)  
11  
12 *the-role-of-authors-and-contributors.html*; accessed August 30th 2016), authorship will be  
13  
14 considered based on contributions to recruitment of patients, data acquisition and cleaning,  
15  
16 analysis and interpretation of data, manuscript writing, and submission of national/local  
17  
18 grants. Authors are required to give final approval of the version to be published and agree  
19  
20 to be accountable for all aspects of the work in ensuring that questions related to the  
21  
22 accuracy or integrity of any part of the work are appropriately investigated and resolved. The  
23  
24 Steering Committee (SC) will also be the Writing Committee (WC).  
25  
26  
27  
28  
29  
30  
31

32 All papers derived from the MOPED database will be published under the acronym “The  
33  
34 MOPED Investigators”. All authors will be specifically named, in order to give every  
35  
36 investigator the same credit and the same responsibilities for successfully performing this  
37  
38 study. All authors will be mentioned with their name and affiliation in the collaborators list  
39  
40 which will be published in an appendix to the manuscript. The members of the Steering-  
41  
42 Writing committee will be specifically identified as required by most journals. Collaborators  
43  
44 names will be listed in PubMed.  
45  
46  
47  
48  
49  
50

51 It is the responsibility of the local coordinators to determine who is to be considered as  
52  
53 investigator. The local PI will be asked to submit names of staff actively involved from their  
54  
55 institution in the End of Study Reporting Form. If the number of recruited patients from a  
56  
57 centre is too low to justify sufficient active involvement, the SC may decide on the legitimacy  
58  
59  
60

1  
2  
3 of collaboratorship based on other contributions. The final decision will be left to the SC in  
4  
5  
6 consultation with the ESA. The number of investigators allowed from each centre will be  
7  
8  
9 determined by the number of patients enrolled by that centre. No more than 25% of a  
10  
11 centre's enrolled patients should be day cases (ambulatory anaesthesia).  
12  
13  
14

15 Presentation at international meetings will be restricted to members of the SC or their  
16  
17 delegates. National Coordinators will qualify for presentation at national meetings after  
18  
19 approval by the SC and the sponsor. ESA Clinical Trial Network will be acknowledged in all  
20  
21 publications and presentations.  
22  
23  
24  
25  
26

27 After publication of the pooled results, centres will be allowed to use their own anonymised  
28  
29 data for local presentation and publication. Duplicate data publication is not permitted.  
30  
31  
32  
33  
34  
35  
36

37 Data availability statement:

38  
39 No additional data available. All relevant data will be uploaded in the published study results.  
40  
41  
42  
43

44 Contributorship statement:

45  
46 D.B., M.C., M.C., J.H., M.H., A.Z. devised the project, D.B., M.C., M.C., J.H., M.H., A.Z.  
47  
48 contributed to the design of the study and developed the protocols for data collection and  
49  
50 analysis. D.B., R.N., M.C., M.C. were involved in the writing of the manuscript. All authors  
51  
52 gave final approval to the publishing of this work. All authors agree to be accountable for the  
53  
54 integrity and veracity of this protocol and the data collected and analysed thereafter.  
55  
56  
57  
58  
59  
60

1  
2  
3 Competing interests:  
4

5  
6 There are no competing interests for any author.  
7  
8  
9  
10  
11  
12  
13  
14

15 Funding:  
16

17  
18 European Society of Anaesthesia as study sponsor is providing administrative support for  
19  
20 data collating. There is no other funding source for this study.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 References:  
33

- 34  
35 1. International diabetes federation, Cho NH, Kirigia J, Claude J et al. IDF diabetes atlas 8<sup>th</sup>  
36  
37 ed. 2019: Visit: <http://www.diabetesatlas.org/resources/2017-atlas.html>. [accessed 22 Jan  
38  
39 2020]  
40  
41  
42 2. Frisch A, Chandra P, Smiley D, et al. Prevalence and clinical outcome of hyperglycaemia  
43  
44 in the perioperative period in non-cardiac surgery. *Diabetes Care* 2010;33:1783-88.  
45  
46  
47 3. Hulst A, Hermanides J, Hollmann MW, DeVries JH, Preckel B. Lack of Consensus on  
48  
49 Peri-Operative Management of Patients with Diabetes Mellitus. *Eur J Anaesthesiol* 2019  
50  
51 Feb;36(2):168-169.  
52  
53  
54 4. Plummer MP, Bellomo R, Cousins CE, et al. Dysglycaemia in the critically ill and the  
55  
56 interaction of chronic and acute glycaemia with mortality. *Intensive Care Med.* 2014  
57  
58 Jul;40(7):973-80. doi: 10.1007/s00134-014-3287-7. Epub 2014 Apr 24.  
59  
60

- 1  
2  
3  
4 5. Umpierrez G, Smiley D, Jacobs S et al. Randomised study of basal-bolus insulin therapy  
5  
6 in the management of patients with type 2 diabetes undergoing general surgery (RABBIT  
7  
8 2 surgery). *Diabetes Care* 2011;34:256-61.
- 9  
10 6. Emily T Martin 1, Keith S Kaye 2, Caitlin Knott. Diabetes and Risk of Surgical Site  
11  
12 Infection: A Systematic Review and Meta-analysis *Infect Control Hosp Epidemiol* 2016  
13  
14 Jan;37(1):88-99. doi: 10.1017/ice.2015.249. Epub 2015 Oct 27.
- 15  
16 7. Vascular events in non-cardiac surgery patients cohort evaluation (VISION  
17  
18 investigators). Association between complications and death within 30 days after  
19  
20 noncardiac surgery. *CMAJ* 2019;191:E830-37.
- 21  
22 8. Kuzulugil D, Papeix G, Luu J, Kerridge R. Recent advances in diabetes treatments and  
23  
24 their perioperative implications. *Current Opinion in Anaesthesiology* 2019;32:398-404.
- 25  
26 9. National Confidential Enquiry into Patient Outcome and Death. Highs and Lows, London,  
27  
28 2018. Visit:  
29  
30 [https://www.ncepod.org.uk/2018pd/Highs%and%20Lows\\_Summary%20Report.pdf](https://www.ncepod.org.uk/2018pd/Highs%and%20Lows_Summary%20Report.pdf).  
31  
32  
33  
34  
35  
36  
37 Accessed 22 January 2020
- 38  
39 10. Garg R, Schuman B, Bader A et al. Effect of preoperative diabetes management on  
40  
41 glycaemic control and clinical outcomes after elective surgery. *Ann Surg* 2018;267:858-  
42  
43 62.
- 44  
45 11. Giuseppe Gatti 1, Andrea Perrotti, Daniel Reichart. Glycated Hemoglobin and Risk of  
46  
47 Sternal Wound Infection After Isolated Coronary Surgery. *Circ J* 2016 Dec 22;81(1):36-  
48  
49 43. doi: 10.1253/circj.CJ-16-0778.
- 50  
51 12. Bell M, Erikson L, Svensson T et al. Days at home after surgery: an integrated and  
52  
53 efficient outcome measure for clinical trials and quality assurance. *E-Clinical*  
54  
55  
56  
57  
58  
59  
60 *Medicine* 2019;11:18-26.



- 1  
2  
3  
4 13. Myles PS, Shulman M, Heritier S et al. Validation of days at home as an outcome  
5  
6 measure after surgery: A prospective cohort study. *BMJ Open* 2017;7:E015828  
7  
8  
9 14. Slankamenac K, Nederlof N, Pessaux P, et al. The comprehensive complications index:  
10  
11 a novel and more sensitive endpoint for assessing outcome and reducing sample size in  
12  
13 randomized controlled trials. *Ann Surg* 2014; 260(5):757-62; discussion 762-3.  
14  
15 15. Clavien PA, Vetter D, Staiger RD, et al. The Comprehensive Complication Index  
16  
17 (CCI(R)): Added Value and Clinical Perspectives 3 Years "Down the Line". *Ann Surg*  
18  
19 2017; 265(6):1045-1050.  
20  
21  
22 16. Stark PA, Myles PS, Burke JA. Development and Psychometric Evaluation of a  
23  
24 Postoperative Quality of Recovery Score. The QoR-15. *Anesthesiology*  
25  
26 2013;118(6):1332-40.  
27  
28  
29 17. Protopappa KL, Simpson JC, Smith N, Moonesinghe R. Development and validation of  
30  
31 the surgical outcome risk tool (SORT). *Br J Surg* 2014;101:1774-83.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure Legend:

**Figure 1: Study work flow**

**Table 1: Study end-points**


| Primary                    | Secondary                                     | Tertiary  |
|----------------------------|---|---|
| Days at Home<br>at 30 days | Comprehensive Complications<br>Index          | Time to resumption of normal<br>diabetes therapy                |
|                            | Quality of Recovery scale (QoR-15)            | Incidence of diabetic ketoacidosis<br>or hypoglycaemia          |
|                            | 30-day mortality                              | incidence and duration of use of<br>IV insulin infusion therapy |
|                            | Length of Stay in Hospital                    | Incidence of diabetic ketoacidosis<br>or hypoglycaemia          |
|                            | Length of Stay in ICU (if applicable)         | Change in diabetic management<br>at 30 days                     |
|                            | Incidence of specific major adverse<br>events |   |

**Table 2. Secondary outcomes and hypotheses of interest**

| Hypothesis   | Variables   |
|--|---|
| There are major differences in perioperative management of diabetic patients in different nations in Europe  | Insulin dose<br>Methods of insulin admin<br>Oral hypoglycaemic use                |
| There are major differences in postoperative morbidity and outcomes among diabetic patients in different nations in Europe   | DAH-30<br>CCI   |
| Outcomes among patients with different strata of glycaemic control, i.e.<br>HbA1c <53,<br>HbA1c 53-69 and<br>HbA1c >69 mmol.mmol will be different;  | Preop HbA1c and glucose<br>DAH-30<br>CCI  |
| Diabetic patient outcomes differ depending on anaesthetic technique:<br><br>Volatile versus total intravenous anaesthesia;<br><br>Regional versus general anaesthesia (GA)<br><br>Combined GA and regional anaesthesia versus patients receiving GA alone. | DAH30<br>CCI<br>All secondary outcomes  |
| Diabetic Patients receiving liberal fluids perioperatively have better outcomes than patients receiving restrictive fluids, compared to their body weight  | DAH-30, CCI<br>crystalloid and colloid totals up to PACU                          |
| Type 2 DM patients have worse outcomes than Type 1   | DAH-30, CCI   |
| Patients where a consultant /senior surgeon and senior anaesthesiologist is present have better outcomes than when not present   | Personnel tracking<br>All Outcomes  |
| Diabetic patients of longer duration experience more hypotension duration/episodes due to autonomic neuropathy and have worse outcomes than diabetic patients with shorter duration  | Intraop and PACU hypotension and use vasopressors and outcomes;<br>Duration of DM |

|   |   |
|---|---|
| NSAID use perioperatively worsens outcomes especially AKI   | DAH30,CCI<br>AKI  |
| Risk factors for higher morbidity in diabetic patients undergoing surgery   | All factors,<br>All outcomes<br>Multivariable analysis    |
| Patients with preoperative GLP-1 use have better perioperative glucose control (and outcome) as compared to other oral hypoglycaemics | Preop medication use DAH30<br>CCI                         |
| There is no association between metformin use and perioperative lactic acidosis   | Preop medication use<br>Incidence of DKA<br>DAH-30<br>CCI |
| Patients with known preoperative susceptibility for hypoglycaemia/DKA are more prone for perioperative hypoglycaemia/DKA              | Preop hypoglycaemia/DKA<br>Periop hypoglycaemia/DKA       |
| Surgery in DM will lead to dysglycaemia up to 30 days   | DM medication at 30 days                                  |

Figure 1: Study Work Flow



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

|                              | Item No | Recommendation  |
|------------------------------|---------|---|
| <b>Title and abstract</b>    | 1       | (a) Indicate the study's design with a commonly used term in the title or the abstract<br>(b) Provide in the abstract an informative and balanced summary of what was done and what was found   |
| <b>Introduction</b>          |         |   |
| Background/rationale         | 2       | Explain the scientific background and rationale for the investigation being reported  |
| Objectives                   | 3       | State specific objectives, including any prespecified hypotheses  |
| <b>Methods</b>               |         |   |
| Study design                 | 4       | Present key elements of study design early in the paper   |
| Setting                      | 5       | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection   |
| Participants                 | 6       | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br>(b) For matched studies, give matching criteria and number of exposed and unexposed   |
| Variables                    | 7       | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable  |
| Data sources/<br>measurement | 8*      | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group  |
| Bias                         | 9       | Describe any efforts to address potential sources of bias   |
| Study size                   | 10      | Explain how the study size was arrived at   |
| Quantitative variables       | 11      | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why  |
| Statistical methods          | 12      | (a) Describe all statistical methods, including those used to control for confounding<br>(b) Describe any methods used to examine subgroups and interactions<br>(c) Explain how missing data were addressed<br>(d) If applicable, explain how loss to follow-up was addressed<br>(e) Describe any sensitivity analyses  |
| <b>Results</b>               |         |   |
| Participants                 | 13*     | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed<br>(b) Give reasons for non-participation at each stage<br>(c) Consider use of a flow diagram   |
| Descriptive data             | 14*     | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders<br>(b) Indicate number of participants with missing data for each variable of interest<br>(c) Summarise follow-up time (eg, average and total amount)  |
| Outcome data                 | 15*     | Report numbers of outcome events or summary measures over time  |
| Main results                 | 16      | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included<br>(b) Report category boundaries when continuous variables were categorized<br>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |

|                          |    |  |
|--------------------------|----|--|
| Other analyses           | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses   |
| <b>Discussion</b>        |    |  |
| Key results              | 18 | Summarise key results with reference to study objectives   |
| Limitations              | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias                 |
| Interpretation           | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence |
| Generalisability         | 21 | Discuss the generalisability (external validity) of the study results  |
| <b>Other information</b> |    |  |
| Funding                  | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based              |

\*Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

# BMJ Open

## Protocol for a prospective, international cohort study on the Management and Outcomes of Perioperative Care among European Diabetic Patients (MOPED)

|                                 |   |
|---------------------------------|---|
| Journal:                        | <i>BMJ Open</i>   |
| Manuscript ID                   | bmjopen-2020-044394.R3  |
| Article Type:                   | Protocol  |
| Date Submitted by the Author:   | 14-Jun-2021   |
| Complete List of Authors:       | buggy , Donal; University College Dublin, ; Nolan, Rachel; Mater Misericordiae University Hospital, Anaesthesia Coburn, Mark; Medical Faculty, RWTH Aachen, Anesthesiology Columb, Malachy; Manchester University NHS Foundation Trust, Wythenshawe Hospital Acute Intensive Care Unit Hermanides, Jeroen; Amsterdam University Medical Centres, Department of Anesthesiology Hollman, M; AMC, Zarbock, Alexander; Universität Münster, |
| <b>Primary Subject Heading</b>: | Anaesthesia   |
| Secondary Subject Heading:      | Diabetes and endocrinology, Surgery   |
| Keywords:                       | Adult anaesthesia < ANAESTHETICS, DIABETES & ENDOCRINOLOGY, SURGERY   |
|                                 |   |

SCHOLARONE™  
Manuscripts





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Title:

**Protocol for a prospective, international cohort study on the Management and Outcomes of Perioperative Care among European Diabetic Patients (MOPED)**

Donal J. Buggy,<sup>1,6</sup> Rachel Nolan<sup>1</sup>, Mark Coburn,<sup>2</sup> Malachy Columb,<sup>3</sup> Jeroen Hermanides,<sup>4</sup> Markus W. Hollmann,<sup>4</sup> Alexander Zarbock.<sup>5</sup>

<sup>1</sup>Department of Anaesthesiology and Perioperative Medicine, Mater University Hospital, School of Medicine, University College Dublin, Ireland;

<sup>2</sup>Department of Anaesthesiology and Perioperative Medicine, University of Bonn, Germany;

<sup>3</sup>Department of Anaesthesiology and Intensive Medicine, Manchester University Hospitals Foundation NHS Trust, Wythenshawe, United Kingdom;

<sup>4</sup>Department of Anesthesiology , Amsterdam University Medical Centers, location AMC, Amsterdam, Netherlands;

<sup>5</sup>Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Muenster, Germany.

<sup>6</sup>Collaborator, Outcomes Research Consortium, Cleveland Clinic, OH, USA.

Corresponding author:

Donal J Buggy donal.buggy@ucd.ie

Funding:

MOPED is sponsored by a grant from the European Society of Anaesthesiology Clinical Trial Network (ESA CTN).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1  
2  
3 Author Contributions:  
4

5 D.B., M.C., M.C., J.H., M.H., A.Z. devised the project, D.B., M.C., M.C., J.H., M.H., A.Z.  
6  
7 contributed to the design of the study and developed the protocols for data collection and  
8  
9 analysis. D.B., R.N., M.C., M.C. were involved in the writing of the manuscript. All authors  
10  
11 gave final approval to the publishing of this work. All authors agree to be accountable for the  
12  
13 integrity and veracity of this protocol and the data collected and analysed thereafter.  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract:**

**Introduction:** Diabetes is common (about 20m patients in Europe), and diabetic patients have more surgical interventions than the general population. There are plausible pathophysiological and clinical mechanisms suggesting that diabetic patients are at increased risk of postoperative complications. When postoperative complications occur in the general population, they increase major adverse events and subsequently increase one-year mortality. This is likely to be worse in diabetic patients. There is variation in practice guidelines in different countries in the perioperative management of diabetic patients undergoing major surgery, and whether this may affect postoperative outcome has not been investigated on a large scale. Neither is it known whether different strata of preoperative glycaemic control affects outcome.

**Methods and analysis:** A prospective, observational, international, multicentre cohort study, recruiting 5,000 diabetic patients undergoing elective or emergency surgery in at least n=50 centres (NCT04511312). Inclusion criteria are any diabetic patient undergoing surgery under any substantive anaesthetic technique. Exclusion criteria are not being a confirmed diabetic patient and diabetic patients undergoing procedures under monitored sedation or local anaesthetic infiltration only. Follow up duration is 30 days after surgery. Primary outcome is Days At Home at 30 days (DAH-30). Secondary outcomes are Comprehensive Complications Index (CCI), Quality of Recovery (QoR-15) Day 1, 30 -day mortality, length of hospital stay and incidence of specific major adverse events (MI, MINS, AKI, PPC, CVA, PE, DVT, Surgical Site Infection (SSI), Postoperative pulmonary infection (PPI)). Tertiary outcomes include time to resumption of normal diabetes therapy, incidence of diabetic

1  
2  
3 ketoacidosis or hypoglycaemia, incidence and duration of use of IV insulin infusion therapy,  
4  
5  
6 and change in diabetic management at 30 days.  
7  
8  
9

10 **Ethics and dissemination:** This study will adhere to the principles of the Declaration of  
11  
12 Helsinki (amendment 2013) by the World Medical Association and the ICH-GCP Guidelines  
13  
14 E6(R2). Specific national and local regulatory authority requirements will be followed as  
15  
16 applicable. Ethical approval has been granted by has been granted by the Institutional  
17  
18 Review Board of the Mater Misericordiae University Hospital, Dublin, Ireland. As enrolment  
19  
20 for this study is ongoing, ethical approval from additional centers is being added  
21  
22 continuously. The main results of MOPED and its sub-studies will be published in peer-  
23  
24 reviewed international medical journals and presented at Euroanaesthesia congress and  
25  
26 other international and national meetings.  
27  
28  
29  
30

31  
32 ClinicalTrials.gov Identifier: NCT04511312  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ARTICLE SUMMARY

### Strengths and limitations of this study:

1. This will be the largest prospective, observational study of the perioperative anaesthetic management of diabetic patients, documenting the influence of perioperative management on 30-day outcomes.
2. The primary endpoint is Days at Home at 30 days (DAH-30), which is a recently validated standardised end-point for perioperative trials (range 0-30 days, higher number indicating better outcome) that gives a patient-centred outcome reflecting mortality, postoperative complications and return to independent living.
3. Secondary outcomes include Comprehensive Complications Index (CCI), a scale 0-100, higher number indicating worse outcome), based on the Clavien-Dindo scale of postoperative complications.
4. Broad inclusion criteria includes confirmed diabetic patients undergoing any surgery under any substantive anaesthetic technique, which will enhance the external validity of the trial results and render it generalisable on a global scale.
5. The power of this study is driven by the target number 5,000 patients, which will enable more than 60 variables to be evaluated and up to eleven a priori hypotheses to be tested.

**Keywords:** Diabetes, perioperative, complications, glycaemic control

**Word Count:** 3,146

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only



## Introduction:

The incidence of diabetes is increasing globally, with an estimated 20 m diabetic patients in Europe. This is likely to increase, adding to societal demands on European health services.[1] Diabetic patients are more likely to have surgical interventions than the general population.[2] There are plausible pathophysiological and clinical mechanisms that diabetic patients are at increased risk of postoperative complications.[3,4] When postoperative complications occur in the general population, they increase mortality or risk of major adverse cardiovascular events (Myocardial Infarction, Cerebrovascular Accident, Pulmonary embolism) at 30-days and up to one year later.[5-7] In addition, diabetes is an independent risk factor for surgical site infections [6].

National bodies in Europe and elsewhere differ in their guidelines on management of diabetic patients undergoing surgery and small observational studies confirm wide variability in practice and perioperative management between centres.[3,8] Given the multiplicity of guidelines and differing recommendations, it is unsurprising that variability of 'real-world' clinical practice regarding perioperative management of oral antihyperglycemic medications and insulin therapy has been observed in audits such as the National Confidential Enquiry into Patient Outcome and Death (NCEPOD).[9] Whether this variability in practice affects postoperative outcome among diabetic patients in Europe or elsewhere has not been investigated.

Further, although it is assumed that diabetic patients are at increased risk of postoperative complications[5-8], this has not been evaluated recently, especially in light of ongoing developments in perioperative care, such as Enhanced Recovery Programmes.[7] While a

1  
2  
3 quality improvement intervention study has shown that maintaining tight preoperative  
4 glycaemic control improves postoperative glycaemic control[10], it is not known if this  
5  
6 reduces postoperative morbidity overall. Moreover, whether certain anaesthetic techniques  
7  
8 may be associated with better or worse outcomes after major non-cardiac surgery is  
9  
10  
11  
12  
13 unknown.

14  
15  
16  
17  
18 Sub-group analysis will provide novel data on how patients with different strata (levels) of  
19  
20 preoperative glycaemic control progress in the postoperative period. Poor pre-operative  
21  
22 glycaemic control is associated with postoperative complications in retrospective  
23  
24 studies[10,11]. If this prospective study confirms an association between the level of  
25  
26 preoperative glycaemic control and postoperative outcome, then the beginning of  
27  
28 personalised perioperative medicine for diabetic patients might be enabled. For example, it  
29  
30 is known from intensive care medicine that patients with better pre-admission glycaemic  
31  
32 control (HbA1c < 53 mmol.mol) have worse outcomes if they develop hyperglycaemia,  
33  
34 compared with patients whose pre-existing glycaemic control was already poor (HbA1c > 69  
35  
36 mmol.mol) [4,11].  
37  
38  
39  
40  
41  
42  
43

44 This large, multicentre, international, prospective observational study will address these  
45  
46 urgent research questions and will inform better management and outcomes for patients  
47  
48 undergoing surgery with this high risk, highly prevalent condition, which is increasing in  
49  
50 incidence in the European population.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Objectives –  
4

5  
6 To address the following research questions:  
7

8  
9  
10 1. What is the epidemiology of diabetic patients undergoing surgery across Europe: Are  
11  
12 there major variations in perioperative glycaemic control? Does management practice vary  
13  
14 between nations?  
15

16  
17 2. What is the extent and patient-centred impact of postoperative complications among  
18  
19 diabetic patients up to 30 days after surgery in Europe?  
20  
21

22 3. To undertake sub-group analysis comparing:  
23

24 a. Type 1, Type 2, and other diabetic patients;  
25

26 b. Patients with different strata (levels) of glycaemic control, i.e. HbA1c <53, HbA1c  
27  
28 53-69 and HbA1c >69 mmol.mol;  
29

30  
31 c. Patients who received different anaesthetic techniques: -Volatile versus total  
32  
33 intravenous anaesthesia; regional versus general anaesthesia (GA);  
34

35  
36 d. Whether diabetic patients of longer duration versus more recently diagnosed  
37  
38 diabetic patients have higher risk of intraoperative hypotension due to autonomic  
39  
40 neuropathy.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

#### Methods and Analysis:

Overall study design - MOPED is a prospective, observational, international, multicentre cohort study, supported by the European Society of Anaesthesiology (ESA). It has been registered on [clinicaltrials.gov](https://clinicaltrials.gov), NCT04511312.

Setting - Any hospital in Europe (as defined by the World Health Organisation) is welcome to participate as a study centre. Non-European centres may be accepted upon request to the Steering Committee. Centres will be asked to enroll a minimum of 45 patients, in order to nominate one named co-investigator. The recruitment period will be up to 18 months from the date of the centre's registration with ESA. No more than one quarter (25%) of a centre's patients can be day cases (ambulatory anaesthesia). Study centre registration will occur online via the dedicated "Call for Centres form" on the ESA website. The start of recruitment for individual centres should be soon as possible after centre registration with ESA, provided that there is prior Institutional Review Board (IRB) approval. It is envisaged that at least n=50 centres will actively enroll patients. It is hoped that patients from at least ten nations will be enrolled. Enrollment will continue until the planned sample size (n=5,000) has been reached.

National coordinating investigators are anaesthesiologists appointed by ESA and the Steering Committee to lead the project within individual countries. Their responsibility includes:

Identifying participating centres in their country and recruiting local co-ordinators in participating hospitals; Ensuring all necessary national or regional regulatory approvals are in place prior to start of patient inclusion; facilitating good communication between ESA headquarters and the participating sites in that nation. Local centre co-ordinators may be

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

anesthesiologists, surgeons or diabetes physician working in perioperative medicine who will ensure all relevant regulatory/ethical approvals are in place for their institution, and who will supervise enrollment, data collection and adjudicate morbidity events.

#### Participants:

Inclusion criteria - Diabetic patients (all classes except gestational diabetes) undergoing surgery with a substantive anaesthetic technique will be included. A substantive anaesthetic technique is defined as one requiring any general anaesthesia or any specific regional anaesthetic technique or a combination. Ambulatory, elective or emergency surgery and patients who receive postoperative care in intensive care or high dependency units will be included. Pre-defined subgroups of diabetic patients will be highlighted for later analysis.

Exclusion criteria - Patients who are not diabetic; Patients with gestational diabetes; Patients undergoing surgery without a substantive anaesthetic technique, i.e. surgery under local anaesthetic infiltration or topical anaesthesia alone with or without monitored sedation .

Criteria for withdrawal or discontinuation of participants - Due to the observational nature of the study, the protocol does not define any withdrawal/discontinuation criteria. Patients electing to withdraw from the study may do so at any point. In this case, no further data will be collected. Previously collected, encoded data will be anonymised and analysis may be performed up to the point of data collection. Withdrawing participants will not be replaced, provided that their number does not exceed 5% of the projected sample size at the end of the planned recruitment period.

1  
2  
3 Participant information and informed consent - Written, informed consent, using the  
4 approved Informed Consent Form (ICF), will be sought from each patient prior to inclusion  
5  
6 unless an explicit, written exemption by the responsible IRB is provided. A Patient  
7  
8 Information Leaflet (PIL) will be provided to patients, and must be subject to local IRB  
9  
10  
11 review and approval.  
12  
13  
14  
15  
16  
17

18 End-Points: (Table 1).  
19

20 Primary end point - Days at Home at 30 days (DAH-30) [12,13]. DAH-30 has been validated  
21  
22 as a patient-centric outcome metric by numerous large scale cohort studies [13] as an  
23  
24 end-point which is pragmatic and easily obtained. It is affected by both patient factors  
25  
26 (poor function, co-morbidities) and surgical technique. DAH-30 is sensitive to surgical risk  
27  
28 and impact of post-operative complications in that it accounts for both delayed discharge  
29  
30 and re-admission.  
31  
32  
33

34 Secondary end points –  
35

36 \*Comprehensive Complications Index (CCI) score, based on Clavien-Dindo scale;[14,15]  
37

38 \*Quality of Recovery scale (QoR-15), only taken from patients who are in hospital the day  
39  
40 after surgery, i.e. Day 1 postoperatively [16],  
41  
42  
43

44 \*30-day mortality,  
45

46 \*Length of Stay in Hospital,  
47

48 \*Length of Stay in ICU if applicable;  
49

50  
51 \*Incidence of specific major adverse events as listed in European Perioperative Clinical  
52  
53 Outcomes Definitions manuscript[17]. These and other outcomes are shown in Table 1.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Data sources: The following data will be extracted from clinical charts: age, gender, weight,  
4 height, variables for CCI, variables for SORT calculation (SORT score).  
5  
6

7  
8 ASA classification, relevant medical history, preoperative diabetes medication (substance  
9 classes only), type of anesthesia, date, type, and location of surgery, procedure duration,  
10  
11 date of ICU admission, date of discharge from ICU.  
12  
13

14  
15 A continuous glucose/insulin infusion will be regarded as planned, any insulin boluses on top  
16  
17 of this infusion will be deemed rescue (or “additional”).  
18  
19

20  
21  
22 Bias - In every centre, all diabetic patients undergoing surgery, (except where there is only  
23  
24 conscious sedation, with or without local anaesthetic infiltration or topical anaesthesia to the  
25  
26 eye) are eligible. Centres are invited to enrol their target number of patients (depending on  
27  
28 number of investigators in their team) from date of registration of their centre with ESA for up  
29  
30 to 18 months. Once they start to enroll patients, centres are asked to do so consecutively,  
31  
32 i.e. to take all eligible diabetic patients one after another. No other exclusion criteria apply,  
33  
34 even emergency surgery patients are eligible. Therefore, we do not believe that significant  
35  
36 risk of bias exists.  
37  
38  
39  
40  
41  
42  
43

44 Study procedures:

45  
46 Recruitment and screening -

47  
48 At screening day (“day -90” to “day of surgery”, i.e. within 3 months of planned day of  
49  
50 surgery), patients may be screened and invited to participate. Diabetic patients listed for  
51  
52 both elective and emergency surgery are eligible. They will be offered a Patient Information  
53  
54 Leaflet and the investigator will withdraw to allow the patient to consider it by alone. The  
55  
56 team member will obtain signed written consent if the patient agrees to proceed. While for  
57  
58  
59  
60

1  
2  
3  
4 elective patients, consent may be obtained in a preoperative clinic up to 90 days prior, for  
5  
6 emergency surgery diabetic patients' consent may be requested on the ward, immediately  
7  
8 prior to coming to theatre on the day of surgery. This is justified because there is even less  
9  
10 knowledge currently about the management and outcomes of diabetic patients undergoing  
11  
12 *emergency* surgery, who are acknowledged to be a particularly high-risk group, compared to  
13  
14 diabetic patients undergoing elective surgery. Therefore, including a cohort of these patients  
15  
16 is particularly important to evaluate risk factors for adverse outcomes which may be  
17  
18 mitigated. There is also anecdotal evidence that practice of managing these patients varies  
19  
20 widely between nations and individual centres. The Surgical Outcome Risk Tool (SORT) will  
21  
22 be used to indicate surgical risk [17]  
23  
24  
25  
26  
27  
28  
29

30 If patients remain in hospital on the day after surgery, QoR-15 quality of recovery score will  
31  
32 be documented. Patient data on insulin use, glucose levels and any complications observed  
33  
34 will also be recorded on Day of Discharge, provided patient is discharged within 30 days of  
35  
36 their surgery. At Day 30 after surgery, data will be collected by telephone if the patient has  
37  
38 been discharged. If still in hospital, patient data will be collected on the ward on Day 30. See  
39  
40

41 Figure 1: Study Flow Table  
42  
43  
44  
45  
46  
47

48 Data collection:

49 At the end of the study period, each center will provide an "end of study reporting form" to  
50  
51 report the number of patients meeting the inclusion criteria during the study period and the  
52  
53 total number of screening failure patients. Furthermore, each center will provide a Screening  
54  
55 Failure Tracking Form giving the reasons for screening failures at the end of the study period.  
56  
57

58 Using this form, it will be possible to analyse what are the reasons for exclusion from study  
59  
60



1  
2  
3 (e.g. subject refused to sign informed consent, subject is already participating in other clinical  
4  
5  
6 trial, subject language, cognitive difficulties, etc). Data will be collected at each centre,  
7  
8 anonymised, and entered into a bespoke electronic case-report form (eCRF). Completed  
9  
10 forms will be submitted to the sponsor at the ESA Clinical Trials Network (ESA CTN) in  
11  
12 Brussels, Belgium.  
13  
14  
15  
16

## 17 Statistical Analysis Plan

### 18 Primary Outcome

19  
20 Descriptive epidemiology of the perioperative management and postoperative morbidity of  
21  
22 Diabetic patients across different countries in Europe. Morbidity and mortality will be  
23  
24 assessed using Days at Home at 30 days (DAH-30) as the primary outcome.  
25  
26  
27  
28  
29

### 30 Secondary Outcomes

31  
32 Secondary outcomes will be morbidity as assessed by the Comprehensive Complications  
33  
34 Index (CCI) score, based on Clavien-Dindo scale and additional hypotheses of interest as  
35  
36 listed in Table 2.  
37  
38  
39  
40  
41  
42  
43  
44  
45

### 46 Sample size estimation

47  
48 Up to 5% of the population of Europe is thought to have diabetes. About 30 million surgeries  
49  
50 are performed in Europe per annum, therefore perhaps 1.5 million diabetics have surgery in  
51  
52 Europe each year. It is proposed to evaluate a pragmatic sample of 5,000 European diabetic  
53  
54 patients across at least 50 centres in a minimum of 10 nations. It is expected that this should  
55  
56 be sufficient for the main epidemiological aspects of this study. It is envisaged that this target  
57  
58  
59  
60

1  
2  
3 number will be enrolled over a two-year period from initial roll-out, with up to a further 12  
4  
5 months needed for final data acquisition, data cleaning and analysis. A sample size of 5,000  
6  
7 should be sufficient to avoid over-fitting and variance inflation for 50 to 70 factors and  
8  
9 interactions based on the conventional square root or 100 values per variable respectively.  
10  
11 In addition, a sample size of 5,000 will have at least 90% power to find a standardized  
12  
13 difference of 0.15 as significant at  $P < 0.05$  (Bonferroni corrected at  $P < 0.0007$ ) for up to 70  
14  
15 independent hypotheses and in comparing subsets of interest.  
16  
17  
18  
19  
20  
21  
22

### 23 **Primary Statistical Analysis**

24  
25 Descriptive statistics such as mean (SD), median [interquartile range] and frequencies (%)  
26  
27 will be presented as appropriate. Gaussian distributions will be assessed using frequency  
28  
29 histograms, normality plots and the Shapiro-Wilks statistic. The precision of the estimates  
30  
31 will be reported as 95% confidence intervals to show the prevalence and incidence rates of  
32  
33 diabetic phenotypes and major adverse events and complications.  
34  
35

36  
37 Continuous data will be analysed using Student  $t$ , Welch  $t$ , Mann-Whitney  $U$ , one-way  
38  
39 analysis of variance (ANOVA) and Kruskal-Wallis  $H$ -statistics. Categorical data will be  
40  
41 analysed using chi-square independence and expanded Fisher exact statistics. Multiple  
42  
43 hypothesis or comparison testing will be addressed using Tukey-Kramer and Bonferroni  
44  
45 corrections and overall statistical significance will be defined at  $P < 0.05$  (two-sided).  
46  
47

48  
49 Repeated measurements in patients will be analysed using generalized linear mixed models  
50  
51 (GLMM) with maximum likelihood estimation (MLE) using appropriate link functions:  
52  
53 Gaussian, Poisson, Negative Binomial and Logit. Robust multivariable linear, logistic,  
54  
55 proportional hazards and quantile regression models will be constructed to identify  
56  
57 significant independent risk factors for adverse outcomes. Variables with  $P < 0.15$  on bivariate  
58  
59  
60

1  
2  
3 analysis, or that are clinically relevant, will be entered. Multicollinearity will be assessed  
4  
5 using variance inflation factors. Hierarchical nesting of patients in hospitals and countries will  
6  
7 be entered as random effects in multilevel mixed-effects GLMM.  
8  
9

### 10 11 12 13 **Secondary Statistical Analysis**

14  
15 Exploratory post-hoc analyses may be performed to gain further information about the cohort  
16  
17 and to assess clinical outcomes with respect to participating countries and hospitals. Any  
18  
19 post-hoc analyses will be identified as such in any reports. Participating institutions can  
20  
21 request data extraction for further analysis and quality improvement, subject to approval of  
22  
23 the Steering Committee. As the primary purpose of this project is epidemiological, missing  
24  
25 data will not be replaced or imputed.  
26  
27  
28  
29  
30  
31

### 32 **Software**

33  
34 Data will be analysed using Stata 16.1, StataCorp Inc., College Station, TX and Number  
35  
36 Cruncher Statistical Systems 2020 (NCSS), NCSS Inc., Kaysville, UT.  
37  
38  
39  
40  
41

42 The Sponsor and the SC have the right to veto the nesting of a study into MOPED. The  
43  
44 publication of any study nested within MOPED will occur after publication of the main results  
45  
46 of MOPED (main objectives 1 and 2). For transparency, the original paper should be  
47  
48 referenced to in all articles of nested analyses. Authorship rules for potential publications  
49  
50 derived from such nested cohort studies are to be submitted to the Sponsor and SC together  
51  
52 with the study proposal.  
53  
54

55  
56 Requests for data sharing for individual-level meta-analyses are to be addressed to the  
57  
58 Sponsor and SC.  
59  
60

1  
2  
3 The sponsor of the study (ESA CTN) can use anonymised pooled data for internal analyses  
4  
5 and educational purposes.  
6  
7  
8  
9

#### 10 GDPR, Data and Quality Management:

11  
12 Quality control measures will be applied to each stage of data handling to ensure that all  
13 data are reliable and have been processed correctly. This will include written SOP (in  
14 English for all countries) for data collection and entry, automated consistency checks, and  
15 training of National Coordinating Investigator and local PI. It will be the responsibility of the  
16 National Coordinating Investigator, with support by the study coordinating office, to train  
17 local PIs. Local centre coordinators will ensure that the data in the eCRF are carefully  
18 entered and verified regularly. It will be the responsibility of local coordinators to conduct  
19 periodic and random checks to ensure data quality in that centre. The ESA as sponsor is  
20 responsible for securing agreement from all involved parties to ensure direct access to all  
21 trial related sites, and source documents for the purpose of monitoring and auditing. No fee  
22 or financial compensation is given to any co-investigator or participating institution for patient  
23 recruitment.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 Data Handling - Data will be entered into a secure on-line database protected by  
45 personalised and confidential usernames and passwords, which document the time and the  
46 individual entering the data. The language of the online database, eCRF, and the relative  
47 SOPs is English and will not be translated into different languages. Data will be collected  
48 directly from source documents into the encoded paper CRF and secondarily entered into  
49 the eCRF. A copy of the original source documents will be stored within a locked  
50 cabinet/office accessible to authorised personnel only in accordance with local and national  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 regulations. All study documents will be archived as required by local legislation. Sponsor  
4  
5 and centres will maintain and update their trial master files according to the recommendation  
6  
7 of the ICH-GCP Guidelines E6(R2).  
8  
9

10  
11  
12  
13 Confidentiality and Data protection - To safeguard patients' confidentiality, a patient  
14  
15 identification code will be assigned to encode data. The confidential log linking patient  
16  
17 identification codes and identifiable patient data will be stored separately in a locked cabinet  
18  
19 accessible to authorised personnel only and corresponding electronic files will be protected  
20  
21 by personalised and confidential usernames and passwords. eCRF are identified through  
22  
23 the patient identification code and will not include any names, initials, date of birth or local  
24  
25 hospital patient numbers. Therefore, no patient identifiable data will be directly accessible  
26  
27 from the eCRF. Open direct access to all relevant trial information as well as source  
28  
29 data/documents will be permitted for purposes of monitoring, audits or inspections by the  
30  
31 sponsor, national coordinators, IRB, or regulatory authorities. All handling of personal data  
32  
33 will comply with the GCP Guidelines and follow strictly the legal and national requirements  
34  
35 for data protection.  
36  
37  
38  
39

40  
41 Patient and Public Involvement – To maximise the benefit of this study to patients, we  
42  
43 prioritised using a patient-centric, holistic primary outcome: Days at Home at 30 days.  
44  
45 Previous Delphi process driven studies have shown this to be a sensitive index of  
46  
47 postoperative complications and their impact on patients' lives. Ireland's diabetes patient  
48  
49 advocacy association, Diabetes Ireland, kindly reviewed the draft protocol and offered  
50  
51 comment and suggestion which influenced the final draft.  
52  
53  
54

55  
56  
57  
58 Publication and dissemination of results:  
59  
60

1  
2  
3  
4 The main results of MOPED and its sub-studies will be published in peer-reviewed  
5  
6 international medical journals and presented at Euroanaesthesia and at international and  
7  
8 national meetings. As recommended by the International Committee of Medical Journal  
9  
10 Editors ([http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-](http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html)  
11  
12 *the-role-of-authors-and-contributors.html*; accessed August 30th 2016), authorship will be  
13  
14 considered based on contributions to recruitment of patients, data acquisition and cleaning,  
15  
16 analysis and interpretation of data, manuscript writing, and submission of national/local  
17  
18 grants. Authors are required to give final approval of the version to be published and agree  
19  
20 to be accountable for all aspects of the work in ensuring that questions related to the  
21  
22 accuracy or integrity of any part of the work are appropriately investigated and resolved. The  
23  
24 Steering Committee (SC) will also be the Writing Committee (WC).  
25  
26  
27  
28  
29  
30  
31

32 All papers derived from the MOPED database will be published under the acronym “The  
33  
34 MOPED Investigators”. All authors will be specifically named, in order to give every  
35  
36 investigator the same credit and the same responsibilities for successfully performing this  
37  
38 study. All authors will be mentioned with their name and affiliation in the collaborators list  
39  
40 which will be published to the manuscript. The members of the Steering-Writing committee  
41  
42 will be specifically identified as required by most journals. Collaborators names will be listed  
43  
44 in PubMed.  
45  
46  
47  
48  
49  
50

51 It is the responsibility of the local coordinators to determine who is to be considered as  
52  
53 investigator. The local PI will be asked to submit names of staff actively involved from their  
54  
55 institution in the End of Study Reporting Form. If the number of recruited patients from a  
56  
57 centre is too low to justify sufficient active involvement, the SC may decide on the legitimacy  
58  
59  
60

1  
2  
3 of collaboratorship based on other contributions. The final decision will be left to the SC in  
4  
5  
6 consultation with the ESA. The number of investigators allowed from each centre will be  
7  
8 determined by the number of patients enrolled by that centre. No more than 25% of a  
9  
10 centre's enrolled patients should be day cases (ambulatory anaesthesia).  
11  
12  
13  
14

15 Presentation at international meetings will be restricted to members of the SC or their  
16  
17 delegates. National Coordinators will qualify for presentation at national meetings after  
18  
19 approval by the SC and the sponsor. ESA Clinical Trial Network will be acknowledged in all  
20  
21 publications and presentations.  
22  
23  
24  
25  
26

27 After publication of the pooled results, centres will be allowed to use their own anonymised  
28  
29 data for local presentation and publication. Duplicate data publication is not permitted.  
30  
31  
32  
33  
34  
35  
36

37 Data availability statement:

38  
39 No additional data available. All relevant data will be uploaded in the published study results.  
40  
41  
42  
43

44 Contributorship statement:

45  
46 D.B., M.C., M.C., J.H., M.H., A.Z. devised the project, D.B., M.C., M.C., J.H., M.H., A.Z.  
47  
48 contributed to the design of the study and developed the protocols for data collection and  
49  
50 analysis. D.B., R.N., M.C., M.C. were involved in the writing of the manuscript. All authors  
51  
52 gave final approval to the publishing of this work. All authors agree to be accountable for the  
53  
54 integrity and veracity of this protocol and the data collected and analysed thereafter.  
55  
56  
57  
58  
59  
60

1  
2  
3 Competing interests:  
4

5  
6 There are no competing interests for any author.  
7  
8  
9  
10  
11  
12  
13  
14

15 Funding:  
16

17  
18 European Society of Anaesthesia as study sponsor is providing administrative support for  
19  
20 data collating. There is no other funding source for this study.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32 References:  
33

- 34  
35 1. International diabetes federation, Cho NH, Kirigia J, Claude J et al. IDF diabetes atlas 8<sup>th</sup>  
36  
37 ed. 2019: Visit: <http://www.diabetesatlas.org/resources/2017-atlas.html>. [accessed 22 Jan  
38  
39 2020]  
40  
41  
42 2. Frisch A, Chandra P, Smiley D, et al. Prevalence and clinical outcome of hyperglycaemia  
43  
44 in the perioperative period in non-cardiac surgery. *Diabetes Care* 2010;33:1783-88.  
45  
46  
47 3. Hulst A, Hermanides J, Hollmann MW, DeVries JH, Preckel B. Lack of Consensus on  
48  
49 Peri-Operative Management of Patients with Diabetes Mellitus. *Eur J Anaesthesiol* 2019  
50  
51 Feb;36(2):168-169.  
52  
53  
54 4. Plummer MP, Bellomo R, Cousins CE, et al. Dysglycaemia in the critically ill and the  
55  
56 interaction of chronic and acute glycaemia with mortality. *Intensive Care Med.* 2014  
57  
58 Jul;40(7):973-80. doi: 10.1007/s00134-014-3287-7. Epub 2014 Apr 24.  
59  
60



- 1  
2  
3  
4 5. Umpierrex G, Smiley D, Jacobs S et al. Randomised study of basal-bolus insulin therapy  
5  
6 in the management of patients with type 2 diabetes undergoing general surgery (RABBIT  
7  
8 2 surgery). *Diabetes Care* 2011;34:256-61.
- 9  
10 6. Emily T Martin 1, Keith S Kaye 2, Caitlin Knott. Diabetes and Risk of Surgical Site  
11  
12 Infection: A Systematic Review and Meta-analysis *Infect Control Hosp Epidemiol* 2016  
13  
14 Jan;37(1):88-99. doi: 10.1017/ice.2015.249. Epub 2015 Oct 27.
- 15  
16 7. Vascular events in non-cardiac surgery patients cohort evaluation (VISION  
17  
18 investigators). Association between complications and death within 30 days after  
19  
20 noncardiac surgery. *CMAJ* 2019;191:E830-37.
- 21  
22 8. Kuzulugil D, Papeix G, Luu J, Kerridge R. Recent advances in diabetes treatments and  
23  
24 their perioperative implications. *Current Opinion in Anaesthesiology* 2019;32:398-404.
- 25  
26 9. National Confidential Enquiry into Patient Outcome and Death. Highs and Lows, London,  
27  
28 2018. Visit:  
29  
30 [https://www.ncepod.org.uk/2018pd/Highs%and%20Lows\\_Summary%20Report.pdf](https://www.ncepod.org.uk/2018pd/Highs%and%20Lows_Summary%20Report.pdf).  
31  
32  
33  
34  
35  
36  
37 Accessed 22 January 2020
- 38  
39 10. Garg R, Schuman B, Bader A et al. Effect of preoperative diabetes management on  
40  
41 glycaemic control and clinical outcomes after elective surgery. *Ann Surg* 2018;267:858-  
42  
43 62.
- 44  
45 11. Giuseppe Gatti 1, Andrea Perrotti, Daniel Reichart. Glycated Hemoglobin and Risk of  
46  
47 Sternal Wound Infection After Isolated Coronary Surgery. *Circ J* 2016 Dec 22;81(1):36-  
48  
49 43.doi: 10.1253/circj.CJ-16-0778.
- 50  
51  
52 12. Bell M, Erikson L, Svensson T et al. Days at home after surgery: an integrated and  
53  
54  
55 efficient outcome measure for clinical trials and quality assurance. *E-Clinical*  
56  
57  
58  
59  
60 *Medicine* 2019;11:18-26.

- 1  
2  
3  
4 13. Myles PS, Shulman M, Heritier S et al. Validation of days at home as an outcome  
5  
6 measure after surgery: A prospective cohort study. *BMJ Open* 2017;7:E015828  
7  
8  
9 14. Slankamenac K, Nederlof N, Pessaux P, et al. The comprehensive complications index:  
10  
11 a novel and more sensitive endpoint for assessing outcome and reducing sample size in  
12  
13 randomized controlled trials. *Ann Surg* 2014; 260(5):757-62; discussion 762-3.  
14  
15 15. Clavien PA, Vetter D, Staiger RD, et al. The Comprehensive Complication Index  
16  
17 (CCI(R)): Added Value and Clinical Perspectives 3 Years "Down the Line". *Ann Surg*  
18  
19 2017; 265(6):1045-1050.  
20  
21  
22 16. Stark PA, Myles PS, Burke JA. Development and Psychometric Evaluation of a  
23  
24 Postoperative Quality of Recovery Score. The QoR-15. *Anesthesiology*  
25  
26 2013;118(6):1332-40.  
27  
28  
29 17. Protopappa KL, Simpson JC, Smith N, Moonesinghe R. Development and validation of  
30  
31 the surgical outcome risk tool (SORT). *Br J Surg* 2014;101:1774-83.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure Legend:

**Figure 1: Study work flow**

**Table 1: Study end-points**


| Primary                    | Secondary                                     | Tertiary  |
|----------------------------|---|---|
| Days at Home<br>at 30 days | Comprehensive Complications<br>Index          | Time to resumption of normal<br>diabetes therapy                |
|                            | Quality of Recovery scale (QoR-15)            | Incidence of diabetic ketoacidosis<br>or hypoglycaemia          |
|                            | 30-day mortality                              | incidence and duration of use of<br>IV insulin infusion therapy |
|                            | Length of Stay in Hospital                    | Incidence of diabetic ketoacidosis<br>or hypoglycaemia          |
|                            | Length of Stay in ICU (if applicable)         | Change in diabetic management<br>at 30 days                     |
|                            | Incidence of specific major adverse<br>events |   |

**Table 2. Secondary outcomes and hypotheses of interest**

| Hypothesis   | Variables   |
|--|---|
| There are major differences in perioperative management of diabetic patients in different nations in Europe  | Insulin dose<br>Methods of insulin admin<br>Oral hypoglycaemic use                |
| There are major differences in postoperative morbidity and outcomes among diabetic patients in different nations in Europe   | DAH-30<br>CCI   |
| Outcomes among patients with different strata of glycaemic control, i.e.<br>HbA1c <53,<br>HbA1c 53-69 and<br>HbA1c >69 mmol.mmol will be different;  | Preop HbA1c and glucose<br>DAH-30<br>CCI  |
| Diabetic patient outcomes differ depending on anaesthetic technique:<br><br>Volatile versus total intravenous anaesthesia;<br><br>Regional versus general anaesthesia (GA)<br><br>Combined GA and regional anaesthesia versus patients receiving GA alone. | DAH30<br>CCI<br>All secondary outcomes  |
| Diabetic Patients receiving liberal fluids perioperatively have better outcomes than patients receiving restrictive fluids, compared to their body weight  | DAH-30, CCI<br>crystalloid and colloid totals up to PACU                          |
| Type 2 DM patients have worse outcomes than Type 1   | DAH-30, CCI   |
| Patients where a consultant /senior surgeon and senior anaesthesiologist is present have better outcomes than when not present   | Personnel tracking<br>All Outcomes  |
| Diabetic patients of longer duration experience more hypotension duration/episodes due to autonomic neuropathy and have worse outcomes than diabetic patients with shorter duration  | Intraop and PACU hypotension and use vasopressors and outcomes;<br>Duration of DM |

|   |   |
|---|---|
| NSAID use perioperatively worsens outcomes especially AKI   | DAH30,CCI<br>AKI  |
| Risk factors for higher morbidity in diabetic patients undergoing surgery   | All factors,<br>All outcomes<br>Multivariable analysis    |
| Patients with preoperative GLP-1 use have better perioperative glucose control (and outcome) as compared to other oral hypoglycaemics | Preop medication use DAH30<br>CCI                         |
| There is no association between metformin use and perioperative lactic acidosis   | Preop medication use<br>Incidence of DKA<br>DAH-30<br>CCI |
| Patients with known preoperative susceptibility for hypoglycaemia/DKA are more prone for perioperative hypoglycaemia/DKA              | Preop hypoglycaemia/DKA<br>Periop hypoglycaemia/DKA       |
| Surgery in DM will lead to dysglycaemia up to 30 days   | DM medication at 30 days                                  |

Figure 1: Study Work Flow



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

|                              | Item No | Recommendation  |
|------------------------------|---------|---|
| <b>Title and abstract</b>    | 1       | (a) Indicate the study's design with a commonly used term in the title or the abstract<br>(b) Provide in the abstract an informative and balanced summary of what was done and what was found   |
| <b>Introduction</b>          |         |   |
| Background/rationale         | 2       | Explain the scientific background and rationale for the investigation being reported  |
| Objectives                   | 3       | State specific objectives, including any prespecified hypotheses  |
| <b>Methods</b>               |         |   |
| Study design                 | 4       | Present key elements of study design early in the paper   |
| Setting                      | 5       | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection   |
| Participants                 | 6       | (a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br>(b) For matched studies, give matching criteria and number of exposed and unexposed   |
| Variables                    | 7       | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable  |
| Data sources/<br>measurement | 8*      | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group  |
| Bias                         | 9       | Describe any efforts to address potential sources of bias   |
| Study size                   | 10      | Explain how the study size was arrived at   |
| Quantitative variables       | 11      | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why  |
| Statistical methods          | 12      | (a) Describe all statistical methods, including those used to control for confounding<br>(b) Describe any methods used to examine subgroups and interactions<br>(c) Explain how missing data were addressed<br>(d) If applicable, explain how loss to follow-up was addressed<br>(e) Describe any sensitivity analyses  |
| <b>Results</b>               |         |   |
| Participants                 | 13*     | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed<br>(b) Give reasons for non-participation at each stage<br>(c) Consider use of a flow diagram   |
| Descriptive data             | 14*     | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders<br>(b) Indicate number of participants with missing data for each variable of interest<br>(c) Summarise follow-up time (eg, average and total amount)  |
| Outcome data                 | 15*     | Report numbers of outcome events or summary measures over time  |
| Main results                 | 16      | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included<br>(b) Report category boundaries when continuous variables were categorized<br>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period |

|    |                          |    |  |
|----|--------------------------|----|--|
| 1  | Other analyses           | 17 | Report other analyses done—eg analyses of subgroups and interactions, and              |
| 2  |                          |    | sensitivity analyses   |
| 3  | <hr/>                    |    |  |
| 4  | <b>Discussion</b>        |    |  |
| 5  | Key results              | 18 | Summarise key results with reference to study objectives                               |
| 6  | Limitations              | 19 | Discuss limitations of the study, taking into account sources of potential bias or     |
| 7  |                          |    | imprecision. Discuss both direction and magnitude of any potential bias                |
| 8  | <hr/>                    |    |  |
| 9  | Interpretation           | 20 | Give a cautious overall interpretation of results considering objectives, limitations, |
| 10 |                          |    | multiplicity of analyses, results from similar studies, and other relevant evidence    |
| 11 | <hr/>                    |    |  |
| 12 | Generalisability         | 21 | Discuss the generalisability (external validity) of the study results                  |
| 13 | <hr/>                    |    |  |
| 13 | <b>Other information</b> |    |  |
| 14 | Funding                  | 22 | Give the source of funding and the role of the funders for the present study and, if   |
| 15 |                          |    | applicable, for the original study on which the present article is based               |
| 16 | <hr/>                    |    |  |

17  
18 \*Give information separately for exposed and unexposed groups.

19  
20  
21 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and  
22 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely  
23 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
24 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
25 available at <http://www.strobe-statement.org>.